AUTHOR INDEX

Arthritis & Rheumatism, Volume 42, Numbers 1–12, 1999

A

Aaron LA, 829
Abbal M, 1093
Abdellatif M, 2325
Abdelmalek MF, 812
Abeles M, 1194, 2372
Abid A, 1951, 2094
Abraham DJ, 930
Abu-Shakra M, 1066
Ackenheil M, 2482
ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature, 599
Adachi M, 100
Adams ME, 993
Adebajo AO, 189, 2497
Aelion JA, 1204
Aggarwal P, 824
Agnello V, 1898
Ahern M, 1068
Ahmed AE, 2132
Ahn C, 268, 1189
Aigner T, 1443, 1946
Aita T, 1508
Aitchison R, 1782
Akahoshi M, 1644
Alaaeddine N, 157, 710
Alarcón GS, 587, 829, 1879, 2731
Albert ED, 1552
Alberts AR, 1655
Alberts KR, 829
Albrecht ME, 545
Alcocer J, 2189
Aldag JC, 585
Algra PR, 2231
Ali MM, 2011
Allen NB, 2250
Alms WJ, 1168
Alten R, 1386
Altman RD, 1159
Alvaro-Gracia JM, 1782
Amengual O, 2606
American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines, 1785
Amiel D, 2123
Amin MA, 1927
Amin S, 1740
Amor B, 580
Amoros JP, 2015
Amos CI, 318, 1071
Amoura Z, 833, 1560, 2734
Amouroux J, 421
Anaya J-M, 1784
Andersen V, 2145
Anderson BE, 2055
Anderson JP, 318
Anderson R, 1087
Ando H, 1961
Andreassen K, 2449
Andremont A, 1056
Andrews B, 1194, 2372
Antohi S, 2656
Aoshima H, 443
Aoyagi T, 2440
Apparailly F, 678
Appelboom T, 1064
Arayssi TK, 1281, 1696, 1889
Arden NK, 1378
Arinobu Y, 1644
Arnason A, 1649
Arnett FC, 268, 465, 1189, 2656
Asai T, 2418
Asanuma Y, 443, 2492
Assendelft WJJ, 1361
Asundi N, 1902
Atamas SP, 561, 1168
Athanassiou P, 1828
Atsumi T, 167, 2461, 2606
Auriault C, 678
Aversa JM, 2705
Axelrod DW, 2309
Axford JS, 1682
Ayral X, 475
Aziz K, 1894

B

Baber U, 1017
Bach J-F, 833, 1062, 2194, 2734
Backhaus M, 1232
Bacon PA, 182
Bae S-C, 1561
Baethge B, 357
Bahram S, 1961
Bai MK, 1559
Balada E, 2260
Baldassare AR, 2153
Bale S, 1696
Balestrieri G, 1412
Bali D, 318
Ballara SC, 819
Ballinger SH, 2213
Balsa A, 989
Bank RA, 1003
Banks MJ, 2491
Barak V, 1421
Barnett ML, 587
Barr SG, 2682
Barr W, 1194, 2372
Barrett E, 1339, 2174
Barrett JH, 757, 1219, 1339
Barrett-Connor E, 1246
Barrier J-H, 2674
Barron KS, 2666
Bartz-Bazzanella P, 1552
Bas S, 942
Basili S, 2689
Baslund B, 2624
Battafarano DF, 1308
Battista JAD, 710
Bayliss MT, 2390
Bayne EK, 1128, 2074
Beckmann N, 119
Belghomari H, 588
Bélisle P, 1722
Bell LA, 825
Bell MC, 2543
Bendele A, 498
Benjamin S, 1397
Benoist C, 2517
Benson LL, 1736
Benton HP, 258
Berdeaux D, 318
Berger D, 871
Berger F, 1773
Bernard CCA, 2569
Bertrand C, 1307
Besis S, 373
Beynon H, 1828
Bickerstaff DR, 2390
Biggs JC, 2286
Bijkerk C, 1729
Bijlsma JWJ, 1003, 1025, 1033, 1361, 2231
Billinghurst RC, 2074, 2381
Bjornsson J, 1255
Black CM, 191, 299, 930, 2646, 2660
Black D, 1246
Black RM, 384
Blakely K, 1691
Blanc AS, 2259
Blanc M, 1773
Blanco R, 826
Bland M, 1682
Blank M, 1421
Blann A, 2646
Blas MS, 383
Blasini AM, 1908
Bläß S, 971, 2499
Bleasel JF, 39
Bliwise DL, 2189
Blobel CP, 1946
Block JA, 577, 2153
Bloom BJ, 2705
Bocaccio C, 2275
Bogdanowicz P, 148
Böhm BB, 1946
Bohne R, 137
Boiardi L, 1562
Boivin GP, 1109
Boling E, 2309
Bollow M, 1232
Bombardier C, 1354, 1870
Bombardieri S, 2249
Bona C, 2656
Bondy B, 2482
Bonetti F, 807
Boomsma MM, 2495
Boots AMH, 1497
Borkowski A, 240
Boschetti C, 197
Bosch-Gil JA, 2489
Botstein GR, 357
Botto M, 1828
Boumediene K, 148
Bourke BE, 2012
Bouscary D, 2275
Bouvet P, 1056
Bowers E, 2646
Bowyer SL, 2213
Boyle DL, 948, 1088
Brack A, 311
Bradley LA, 829, 2731
Branch DW, 318, 1309
Brand CA, 2569
Brand F, 306
Brandt KD, 545, 1140, 1267
Branigan PJ, 1889
Braun J, 196, 832, 1386, 2039
Brautbar C, 1010
Breban M, 580, 2275
Bredholt G, 2583
Breedveld FC, 650, 948, 1473, 1729, 1854, 2166, 2198, 2430
Brennan P, 1219
Bresnihan B, 1782
Brey R, 1309
Bridgeford PH, 2055
Brissot P, 799
Brockbank J, 189
Brooks PM, 2286
Brooks WM, 2026
Broyles TF, 69
Brucato A, 1757
Brühl H, 981
Brühlmann P, 389, 622
Brundula V, 1908
Bruner GR, 1902
Brunkhorst R, 2020
Brunner HI, 1354, 2346
Brush M, 2281
Bryan C, 2660
Bucala R, 1601
Buchanan TS, 25, 861, 2735
Buchs N, 963
Buckley C, 182
Buckley LM, 1736
Bullough PG, 2719
Buma P, 2074, 2381
Bunker CB, 448
Burdt MA, 899
Burgos-Vargas R, 2160
Buring JE, 910
Burkhardt H, 1946
Burmester G-R, 395, 578, 697, 971, 1232, 2499
Burt RK, 2281
Buskila D, 1066
Bustillo J, 1204
Butcher BT, 455
Buttgereit F, 395
Buyon JP, 2335
Buys S, 1833
Buzás EI, 2524
Byrne VM, 1322

AUTHOR INDEX

Arthritis & Rheumatism, Volume 42, Numbers 1–12, 1999

A

Aaron LA, 829
Abbal M, 1093
Abdellatif M, 2325
Abdelmalek MF, 812
Abeles M, 1194, 2372
Abid A, 1951, 2094
Abraham DJ, 930
Abu-Shakra M, 1066
Ackenheil M, 2482
ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature, 599
Adachi M, 100
Adams ME, 993
Adebajo AO, 189, 2497
Aelion JA, 1204
Aggarwal P, 824
Agnello V, 1898
Ahern M, 1068
Ahmed AE, 2132
Ahn C, 268, 1189
Aigner T, 1443, 1946
Aita T, 1508
Aitchison R, 1782
Akahoshi M, 1644
Alaaeddine N, 157, 710
Alarcón GS, 587, 829, 1879, 2731
Albert ED, 1552
Alberts AR, 1655
Alberts KR, 829
Albrecht ME, 545
Alcocer J, 2189
Aldag JC, 585
Algra PR, 2231
Ali MM, 2011
Allen NB, 2250
Alms WJ, 1168
Alten R, 1386
Altman RD, 1159
Alvaro-Gracia JM, 1782
Amengual O, 2606
American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines, 1785
Amiel D, 2123
Amin MA, 1927
Amin S, 1740
Amor B, 580
Amoros JP, 2015
Amos CI, 318, 1071
Amoura Z, 833, 1560, 2734
Amouroux J, 421
Anaya J-M, 1784
Andersen V, 2145
Anderson BE, 2055
Anderson JP, 318
Anderson R, 1087
Ando H, 1961
Andreassen K, 2449
Andremont A, 1056
Andrews B, 1194, 2372
Antohi S, 2656
Aoshima H, 443
Aoyagi T, 2440
Apparailly F, 678
Appelboom T, 1064
Arayssi TK, 1281, 1696, 1889
Arden NK, 1378
Arinobu Y, 1644
Arnason A, 1649
Arnett FC, 268, 465, 1189, 2656
Asai T, 2418
Asanuma Y, 443, 2492
Assendelft WJJ, 1361
Asundi N, 1902
Atamas SP, 561, 1168
Athanassiou P, 1828
Atsumi T, 167, 2461, 2606
Auriault C, 678
Aversa JM, 2705
Axelrod DW, 2309
Axford JS, 1682
Ayral X, 475
Aziz K, 1894

B

Baber U, 1017
Bach J-F, 833, 1062, 2194, 2734
Backhaus M, 1232
Bacon PA, 182
Bae S-C, 1561
Baethge B, 357
Bahram S, 1961
Bai MK, 1559
Balada E, 2260
Baldassare AR, 2153
Bale S, 1696
Balestrieri G, 1412
Bali D, 318
Ballara SC, 819
Ballinger SH, 2213
Balsa A, 989
Bank RA, 1003
Banks MJ, 2491
Barak V, 1421
Barnett ML, 587
Barr SG, 2682
Barr W, 1194, 2372
Barrett E, 1339, 2174
Barrett JH, 757, 1219, 1339
Barrett-Connor E, 1246
Barrier J-H, 2674
Barron KS, 2666
Bartz-Bazzanella P, 1552
Bas S, 942
Basili S, 2689
Baslund B, 2624
Battafarano DF, 1308
Battista JAD, 710
Bayliss MT, 2390
Bayne EK, 1128, 2074
Beckmann N, 119
Belghomari H, 588
Bélisle P, 1722
Bell LA, 825
Bell MC, 2543
Bendele A, 498
Benjamin S, 1397
Benoist C, 2517
Benson LL, 1736
Benton HP, 258
Berdeaux D, 318
Berger D, 871
Berger F, 1773
Bernard CCA, 2569
Bertrand C, 1307
Besis S, 373
Beynon H, 1828
Bickerstaff DR, 2390
Biggs JC, 2286
Bijkerk C, 1729
Bijlsma JWJ, 1003, 1025, 1033, 1361, 2231
Billinghurst RC, 2074, 2381
Bjornsson J, 1255
Black CM, 191, 299, 930, 2646, 2660
Black D, 1246
Black RM, 384
Blakely K, 1691
Blanc AS, 2259
Blanc M, 1773
Blanco R, 826
Bland M, 1682
Blank M, 1421
Blann A, 2646
Blas MS, 383
Blasini AM, 1908
Bläß S, 971, 2499
Bleasel JF, 39
Bliwise DL, 2189
Blobel CP, 1946
Block JA, 577, 2153
Bloom BJ, 2705
Bocaccio C, 2275
Bogdanowicz P, 148
Böhm BB, 1946
Bohne R, 137
Boiardi L, 1562
Boivin GP, 1109
Boling E, 2309
Bollow M, 1232
Bombardier C, 1354, 1870
Bombardieri S, 2249
Bona C, 2656
Bondy B, 2482
Bonetti F, 807
Boomsma MM, 2495
Boots AMH, 1497
Borkowski A, 240
Boschetti C, 197
Bosch-Gil JA, 2489
Botstein GR, 357
Botto M, 1828
Boumediene K, 148
Bourke BE, 2012
Bouscary D, 2275
Bouvet P, 1056
Bowers E, 2646
Bowyer SL, 2213
Boyle DL, 948, 1088
Brack A, 311
Bradley LA, 829, 2731
Branch DW, 318, 1309
Brand CA, 2569
Brand F, 306
Brandt KD, 545, 1140, 1267
Branigan PJ, 1889
Braun J, 196, 832, 1386, 2039
Brautbar C, 1010
Breban M, 580, 2275
Bredholt G, 2583
Breedveld FC, 650, 948, 1473, 1729, 1854, 2166, 2198, 2430
Brennan P, 1219
Bresnihan B, 1782
Brey R, 1309
Bridgeford PH, 2055
Brissot P, 799
Brockbank J, 189
Brooks PM, 2286
Brooks WM, 2026
Broyles TF, 69
Brucato A, 1757
Brühl H, 981
Brühlmann P, 389, 622
Brundula V, 1908
Bruner GR, 1902
Brunkhorst R, 2020
Brunner HI, 1354, 2346
Brush M, 2281
Bryan C, 2660
Bucala R, 1601
Buchanan TS, 25, 861, 2735
Buchs N, 963
Buckley C, 182
Buckley LM, 1736
Bullough PG, 2719
Buma P, 2074, 2381
Bunker CB, 448
Burdt MA, 899
Burgos-Vargas R, 2160
Buring JE, 910
Burkhardt H, 1946
Burmester G-R, 395, 578, 697, 971, 1232, 2499
Burt RK, 2281
Buskila D, 1066
Bustillo J, 1204
Butcher BT, 455
Buttgereit F, 395
Buyon JP, 2335
Buys S, 1833
Buzás EI, 2524
Byrne VM, 1322

C

Cacoub P, 1545, 1560, 2204
Cafforio P, 1967
Cailleux N, 2002
Caldwell JR, 357, 2153
Callard P, 421
Campana S, 1305
Campbell PL, 1927
Campos RM, 2189
Canete JD, 1481
Cannon GW, 2153
Canovas F, 678
Cantagrel A, 1093
Cantini F, 1562
Caplan AI, 2631
Carbone LD, 1204
Cardellach F, 1051
Carlson CS, 2103
Carlson D, 2705
Carlson RP, 2060
Carr G, 1894
Carreira PE, 989
Carroll GJ, 2543
Carruthers DM, 182
Cartman A, 527
Carvalho D, 631
Casademont J, 1051
Casassus P, 421
Casato M, 2007
Caspi D, 2561
Castaño VA, 2189
Catheline M, 799
Cazarín-Barrientos J, 2160
Cevallos R, 421
Chabaud M, 963
Chaisson CE, 33, 306
Chalès G, 799
Changlai S-P, 61
Chansky HH, 1443
Chapman HM, 2543
Chapman MJ, 373
Charlotte F, 2204
Chartash EK, 1655
Chat M, 1951
Chaudhuri TR, 641
Chaussade S, 1545
Chen J, 1813
Chen JJ, 438
Chen PP, 2132
Chen Y, 1986
Cheney CP, 573
Chernajovsky Y, 90
Cherpes T, 2103
Cheung HS, 555
Chevrel G, 1773
Chieng P-U, 61
Chines AA, 2309
Chinn R, 735
Chiorazzi N, 1655
Chiu B, 1662
Chlipala E, 498
Cho C-S, 2085
Cho M-L, 2085
Choi HK, 384
Chow J, 2012
Christian CL, 1291, 1321
Christner PJ, 581
Chu CC, 1655
Chu J-L, 1833
Chukwudelunzu FE, 2243
Churchill M, 1691
Ciabattoni G, 2689
Cid MC, 190, 1051, 2257
Cihak J, 981
Cipolletta C, 2094
Cipollone F, 2689
Cirigliano G, 2249
Clark AG, 2356
Clarke AE, 1722
Clegg DO, 1879, 2325
Clements PJ, 1194, 2372
Cloutier J-M, 710, 1147, 1577
Cobby M, 1782
Coblyn JS, 1322
Coburn J, 2705
Cohen MD, 2243
Cohen S, 1421, 2309
Cohen Tervaert JW, 2495
Cole AA, 719
Collado A, 2319
Collier D, 1194, 2372
Coll-Vinent B, 190, 1051, 2257
Colombo G, 1757
Coluccio E, 1757
Compasso S, 1757
Conaghan PG, 1080, 1706, 1998, 2184
Congia M, 1497
Conn D, 455
Connor JR, 1588
Constantin A, 1093
Cook AD, 2569
Cook NR, 910
Cooke SP, 448
Cope AP, 1497
Copel J, 2335
Cordoliani F, 2259
Corlett L, 1040
Cortes F, 2260
Courtois H, 2002
Coutlée F, 1307
Coutts RD, 2123
Couturier D, 1545
Coviello R, 2007
Cox C, 2239
Crane M, 1281
Crassard I, 2194
Crawford B, 1870
Crawley E, 590, 1101, 2017
Cremer MA, 1204
Crisci C, 1304
Criswell LA, 438
Crosti M, 1412
Crow MK, 871
Crowson CS, 415
Crutchfield M, 483
Csernok E, 742
Cs-Szabó G, 2524
Cucchi-Mouillot P, 2015
Cucurull E, 1655
Cummings SR, 854, 1246, 1378
Cuppari GG, 1302
Czerkinsky C, 1628

D

Dafni UG, 1765
Dammacco F, 1967
Dammacco R, 1967
Dantec PL, 799
Date Y, 2577
Davì G, 2689
Davidson A, 1291
Davies KA, 1828
Dawes PT, 2698
Dawkins R, 455
Dawson J, 119
Deal C, 2153
De Benedetti F, 807
de Buck M, 1854
Decaris E, 1951
DeGroot J, 1003
de Jonge S, 2482
de Juan MD, 989
De Keyser F, 1067
Dekker J, 1361
de la Sierra A, 190, 2257
Delgado J, 1784
Delgado-Rodriguez M, 826
Del Papa N, 197
Delrieu O, 2194
Del Rincón I, 1329, 1712, 2498
del Río A, 1051
Dennis K, 659
Denton CP, 299, 2646
Derksen R, 1309
De Rosa FG, 2007
Deshpande S, 1040
DeSimone M, 318
Deugnier Y, 799
Deutscher SL, 899
Devogelaer J-P, 1159, 1405, 1861
de Vries N, 1621
Dharmavaram RM, 1433
Di Battista JA, 157, 2399
Dick T, 1552
Dickson DW, 2243
Dietrich H, 581
Dietz F, 357
di Girolamo C, 1304
Dijstelbloem HM, 1823
Dimitriou ID, 229
Dinser R, 574
Disla E, 1302
Distler O, 389, 1296
Di Vico B, 2007
Dixey J, 1557
Dodds RA, 1588
Doherty M, 1782
Domljan Z, 1782
Donald F, 780
Dönitz H, 697
Donnelly P, 1843
Dörner T, 697
Dorrier C, 1870
Doud D, 1691
Dougados M, 475, 580, 2275
Doyle DV, 17
Dragomir AD, 2356
Drake FH, 1588
Drappa J, 1833
Dreyfus F, 2275
Driscoll PC, 1040
Drosos AA, 1559
Drossaers-Bakker KW, 1854
Druetz-Van Egeren A, 1159
Du LTH, 1560
du Bois R, 448
Du Clos T, 1300
Duffy J, 186
Dunlop DD, 25, 861, 882, 2735
Dunn JE, 882
Dupuis M, 1147
Durand JM, 963
Durand-Gasselin B, 421
Duval N, 2112
Duwel LE, 1109
Dwek RA, 1682
Dziadzio M, 2646

E

Eastwood JB, 2012
Eberhardt K, 347
Eckhoff PJ, 1691
Edberg JC, 2601
Eggens U, 1386
Eguchi K, 2440
Ehlers PF, 993
Einsele H, 1485
Eiter V, 981
Ekman P, 84
Elagib KEE, 2471
Eldor A, 1421
Elewaut D, 1067
El-Gabalawy HS, 1696
Elisaf M, 373
Elkon KB, 1833
Emery P, 1080, 1481, 1706, 1782, 1998, 2184
Emery V, 448
Emkey RD, 2309
Enault G, 1093
Enders JT, 2524
Engel J-M, 971, 2499
Enzenauer RJ, 573, 1061, 1308
Epstein WV, 1781
Erdman DD, 1255
Escalante A, 1329, 1712
Esdaile J, 527
Espy M, 1255
Estrada J, 1833
Ettlinger R, 357
Euler HH, 1552
European Concerted Action on Sjögren's Syndrome Members, 1765
Evans CH, 1, 248, 490
Evans SR, 306, 2153
Exley AR, 182
Eyre S, 1617

F

Fahmy A, 1302
Farber HW, 2638
Farewell VT, 189
Farris AD, 199
Fascio U, 1412

Fautrel B, 475
Feezor R, 1736
Feghali CA, 1451
Feist E, 578, 697
Feldman BM, 1354
Feldmann M, 1779
Felisaz N, 148
Feller AC, 751
Felman C, 1773
Felson DT, 25, 33, 306, 861, 1069, 1740, 2153, 2735
Fendler C, 1386
Ferland D, 1722
Fernandes J, 157
Fernihough JK, 2103
Ferrari R, 828
Ferro D, 2689
Fiaschetti P, 2007
Fiddler M, 1219
Field JA, 1813
Figueroa M, 826, 989
Fiorilli M, 2007
Firestein GS, 609, 948, 1088, 1594
Fischer D-C, 1936
Fishman M, 2281
Fisk JD, 728
Fitzcharles M-A, 527
Fitzgerald O, 2724
Fitzgerald SG, 51, 882
Fleck M, 641
Fleischmann R, 2153
Flusser D, 1066
Foeldvari I, 396
Font C, 190, 2257
Ford P, 318
Fortin PR, 1722
Fossel AH, 1722
Fossiez F, 963
Fracture Intervention Trial Research Group, 1246
Fraenkel L, 306
Francès C, 1560, 2194, 2259
Franceschini F, 1757
Franco MD, 2689
François A, 2002
Franklin BN, 490
Frappart L, 963
Fraser P, 1561
Frassanito MA, 1967
Frazier J, 498
Freedman M, 2346
French Vasculitis Study Group, 2674
Freudiger D, 1517
Friedman D, 2335
Frigelli S, 2249
Friger M, 1066
Fritz J, 1232
Fritz P, 1485
Fritzler MJ, 455
Fujimoto S, 2727
Fujita A, 1549
Fuller A, 2286
Furie RA, 1655
Furst DE, 357, 1194, 1556, 2153, 2269, 2372
Furuichi I, 2440

G

Gabriel SE, 46, 415, 1255, 2022
Galanski M, 2736
Galera P, 148
Gallagher J, 2524
Gallivan S, 1557
Garbarsch C, 2624
García FJB, 383
García-Porrúa C, 1561
Garcia Ramos G, 2189
Garred P, 2145
Garson JA, 2492
Gaston JSH, 2239
Gatus B, 1894
Gaudin P, 2492
Gause A, 2507
Gause WC, 561
Gay RE, 389, 490, 622
Gay S, 389, 490, 622, 1517, 1594
Gayraud M, 421
Gehrsitz A, 1946
Gelfand SG, 830
Gellrich S, 240
Genant HK, 1246, 1558
Gendreau RM, 2153
Généreau T, 2674
Genetet B, 2015
Geng CS, 1147
Genth E, 1552
Georganas C, 2281
Georgescu HI, 248
Gérard HC, 1281, 1889
Gerber I, 187
Gerneth F, 1485
Gharavi AE, 1309, 1655
Ghillani P, 2204
Ghivizzani SC, 1
Gianis K, 1601
Giannini EH, 1843, 2213, 2261
Gibbon W, 1706
Gibney RG, 2724
Gibson AW, 2601
Gideon P, 918
Gillet P, 1951
Gillies JH, 2735
Giraudeau B, 475, 1556
Gladman DD, 189, 822, 1228
Glant TT, 2524
Glass DN, 1843, 2261
Glatzeder K, 2482
Glickstein L, 1813
Glück T, 1296
Goding J, 1986
Goel N, 318
Goker B, 577
Goldbach-Mansky R, 1696
Goldberg VM, 2631
Golden HE, 357
Goldkorn T, 1421
Goldring MB, 1986
Golembowski S, 240
Gombert B, 580
Gómez-Reino JJ, 989, 2733
Gómez-Zumaquero JM, 2606
Gompel A, 2259
Gonzalez EB, 825
Gonzalez M, 1204
González MF, 383
Gonzalez S, 1010
González-Gay MA, 826, 1561
Gonzalez-Roces S, 1010
Goodfield M, 1998
Gooi J, 2184
Gordon C, 1828
Gordon T, 455
Gore LR, 854, 1378
Goronzy JJ, 311, 589, 844, 2258
Goto K, 1961
Gourley IS, 318
Gowen M, 1588
Goycochea MV, 2160
Grabowska A, 2552
Graeve L, 1936
GRAID Research Group, 2194
Granfors K, 84, 1386, 2045, 2239
Grant SFA, 285
Gratacós J, 2319
Gratz KF, 2736
Grau JM, 190, 1051, 2257
Gray-McGuire C, 1902
Graziano F, 2281
Green DR, 1088, 1594
Green M, 1706, 2184
Greenwald M, 2309
Gregersen PK, 1071, 1655
Griffing WL, 812
Griffiths DJ, 448, 2493
Grillasca J-P, 1951
Gringhuis S, 2430
Gripenberg-Lerche C, 1386
Grismer LE, 1065
Grodzicky T, 1347
Groh A, 1386
Gromnica-Ihle E, 240, 1517
Gröndal G, 1649
Gross WL, 742, 751, 1752, 2507
Gruber R, 981
Guedes C, 588
Guerassimov A, 527
Guerin C, 475
Guggenbuhl P, 799
Guillevin L, 421, 1062, 2674
Guillou GB, 148
Guimond M, 1347
Guingamp C, 1951
Gulko P, 1696
Gunnlaugsdottir B, 1649
Gur-Lavi M, 1777
Gushiken FC, 1189
Gustard S, 119
Gyimesi E, 1673

H

Hachulla E, 2674
Haerten R, 2303
Hahn BH, 2132
Hain NAK, 971
Haire CE, 1691
Hajeer A, 448, 1561, 1617, 2698, 2732
Halberg P, 2145
Hale G, 1998
Hall F, 1497
Hall P, 1601
Hall-Craggs MR, 735
Hamann J, 650
Hamm B, 1232
Hammond LA, 182
Han H, 1285
Han Z, 1088
Hanaoka R, 100
Handa R, 824
Handler RP, 1556
Handwerger BS, 561
Hanley SD, 2724
Hanly JG, 728
Hanna MP, 1267
Hansen A, 578
Hansen KE, 2250
Hansen M, 918, 2624
Haqqi TM, 397
Hara T, 1298
Harada S, 1508
Haras D, 2015
Hardin JA, 455
Harley JB, 199, 1017, 1782, 1902
Harlow LA, 1927
Harris EN, 1309
Harris ER, 2153
Harris MD, 1065
Harris RR, 2060
Harrison B, 757, 1339, 2174
Hart DJ, 17
Hart DNJ, 507
Harth M, 76
Hashimoto H, 221
Hashimoto S, 1655, 2123
Hashiramoto A, 954
Hassager C, 790
Hassell AB, 2698
Hasty KA, 719, 1140
Hasunuma T, 519, 686
Hatano Y, 100
Hau M, 2303
Haubeck H-D, 1936
Haubitz M, 2020
Hawke S, 1040
Hayakawa K, 2729
Hayem G, 1056
Hayes KW, 25, 861
Hazes JMW, 1854
He Q, 2045
Heinegård D, 39
Heinrich P-C, 1936
Heiser A, 507
Helfgott SM, 828, 1312, 1322
Hellmann DB, 2365
Hellmich B, 1752
Henderson CJ, 790
Hennekens CH, 910
Henry P, 1168
Hernandez J, 2705
Hernández-Rodríguez J, 1051
Herndon JH, 1
Herrick AI, 299
Herson S, 2674
Hervé C, 448
Heshmati F, 2275

Heymans PHM, 1473
Heyse SP, 1879
Hicks JE, 2213
Hida A, 2440
Hidaka T, 431, 2255
Hiepe F, 196, 578, 697, 1386
Highton J, 507
Higuchi T, 2577
Hilal G, 2112
Hill NS, 2638
Hirakata H, 1644
Hirata T, 2577
Hirohata S, 593, 2729
Hirose N, 1655
Hirsch R, 1109
Ho Y-J, 61
Hochberg MC, 483, 854, 1246, 1378
Hoffman GS, 2496
Hoffman RW, 190, 703, 899
Hoffmann A, 574
Hofman A, 1729
Hogue R, 1902
Holderbaum D, 39, 397
Holdsworth SR, 1601
Holers VM, 2023
Hollander AP, 137, 2381, 2390
Hollis B, 483
Holly JMP, 2103
Holmdahl R, 1628
Holmgren J, 1628
Holmström T, 2045
Holthuysen AEM, 1128, 2074
Holyst M-M, 703
Homma T, 1609
Hong C, 728
Horiuchi T, 1644
Horsfall AC, 199
Houssiau FA, 1405
Houwing-Duistermaat JJ, 1729
Howard RF, 465
Howell K, 2646
Huang C, 110
Huang C-F, 882
Huang D, 993
Huber BT, 1813
Hubers HAJM, 1497
Hubscher O, 69
Hudson AP, 1281, 1889
Huebner JL, 590
Hughes GRV, 1309, 2461, 2606
Hui W, 2543
Hunder GG, 1255, 1259
Hurwitz EL, 2372
Hutchinson I, 1101
Hutchinson P, 1538, 1601

I

Ichikawa K, 167, 2461, 2727
Ichinose Y, 2440
Ida H, 2440
Ide H, 100
Ieko M, 167
Ieong MH, 2638
Ihara K, 1298
Ilardi I, 2007
Infante R, 1302
Inman RD, 1662
Inoko H, 1961
Ionescu M, 39, 129, 534
Isaacs J, 1998
Isenberg DA, 191, 590, 631, 735, 1765, 1783, 1828, 2017
Ishiguro N, 129
Ishizuka T, 431
Isshi K, 593
Ito H, 129
Ito T, 129
Itoh K, 2577
Iwamoto M, 1549
Iwata H, 129

J

Jacobs JWG, 2231
Jacobsen S, 2145
Jacobson PB, 2060
Jacquet C, 678
Jaeger C, 981
Jahn S, 240
Jahns R, 2303
Jain RI, 1655
Jalava J, 84
Jamadar D, 483
James JA, 69, 1017, 1782
Jameson-Shortall E, 735
Jang D, 2410
Janicka I, 2552
Jannausch ML, 483
Jarrousse B, 421
Jauberteau MO, 2256
Jayne DRW, 2019
Jeanneret J, 1773
Jeffery DR, 569
Jenett M, 2303
Jensen KE, 918
Ji H, 2517
Jiang Y, 438
Jiménez SA, 581, 1433
Jin-Hua P, 1986
Johansen JS, 2624
John S, 1617
Johnson JC, 899
Johnson K, 1986
Johnstone B, 2631
Jones P, 39
Jönsson B, 347
Jönsson L, 347
Jonsson R, 2471
Joo K, 2577
Jordan JM, 2356
Jorgensen C, 678
Joseph L, 1722
Jouanolle A-M, 799
Jouquan J, 1062
Jouzeau J-Y, 2094
Jovanovic D, 2399
Judex M, 1594
Judovich R, 2561
Jugessur H, 129, 534
Jüsten H-P, 1594
Juvenile Dermatomyositis Disease Activity Collaborative Study Group, 2213

K

Kaburaki J, 275, 443, 465, 1179
Kaeley G, 1204
Kaganovsky E, 1421
Kahn M-F, 1056
Kaku Y, 1298
Kalden JR, 455, 1946
Kallenberg CGM, 1823
Kamin M, 1370
Kamizono S, 2577
Kammer GM, 1458
Kamogawa J, 2616
Kamradt T, 1232
Kanagawa S, 2612
Kanda N, 328
Kaneda Y, 2532
Kaneko A, 2418
Kaneko M, 221, 2532
Kanemitsu S, 1298
Kang AH, 1204
Kang R, 1
Kanik KS, 2055
Kannel W, 33
Kao C-H, 61
Kaplan SB, 1204
Kapsogeorgou EK, 229
Karabina S-AP, 373
Karlson EW, 910
Karpusas M, 1291
Karten I, 1302
Kasama T, 100
Kassis N, 1056
Katada Y, 1635
Kataharada K, 431
Kato EH, 2727
Kato H, 954, 2577
Kato K, 2532
Kato T, 686
Katsuyama Y, 1961
Katz BP, 1267
Katz JN, 1722
Katz PP, 2710
Kaufman KM, 1017
Kaufman RL, 406
Kawabe Y, 2440
Kawahito Y, 954
Kawai S, 443, 2492
Kawakami A, 2440
Kawakami M, 431
Kawashima M, 1508
Kay R, 590, 1101
Kaymakcian MV, 1322
Keberle M, 2303
Keen RW, 285, 1068
Keitel W, 1386
Keller E, 1552
Keller M, 2309
Kelly J, 1902
Khakoo AY, 1291
Khamashta MA, 1309, 2461, 2606
Khoa ND, 686
Kiansa K, 710
Kiely PDW, 2012
Kieval RI, 828
Kilcoyne RF, 1550, 1559
Kim H-A, 1285, 1528
Kim H-Y, 2085
Kim JH, 659
Kim S-I, 2085
Kim SY, 818
Kim T-H, 818
Kim W-U, 2085
Kimberly RP, 2601
Kimoto M, 2593
Kimura A, 2577
Kimura S, 954
Kimura T, 669, 1297, 2014
King M-C, 438
Kingsmore SF, 318
Kirou KA, 871
Kirveskari J, 2045
Kirwan JR, 1066
Kirwan-Mellis G, 25, 861, 2735
Kishimoto T, 1635
Kishner S, 1304
Kitagawa M, 1917
Kitas GD, 2491
Klareskog L, 1649
Klarlund M, 918
Klassen LW, 1691
Kleinman HK, 1051
Klings ES, 2638
Klippel JH, 1281, 1696
Kloetzel P-M, 697
Knight C, 2660
Knight GB, 1898
Knitzer RH, 561
Koarada S, 2593
Kobata T, 519, 686
Kobayashi K, 100
Kobayashi S, 291, 2461
Kobayashi T, 519
Kobelt G, 347
Koch AE, 1927
Koch S, 1485
Kohsaka T, 1644
Koike T, 167, 1309, 2461, 2727
Kondo M, 291, 954
Kontny E, 2552
Koolpe M, 258
Koop I, 806
Korganow A-S, 2517
Korn JH, 2638
Koshiba M, 2612
Koshy M, 871
Kostyu DD, 318
Kotilainen P, 84
Kouskoff V, 2517
Koutouzov S, 833, 2734
Kowalczewski J, 2552
Kozaci LD, 137
Koziol JA, 455
Kraan MC, 948
Krafchik BR, 2656
Kraft K, 1553
Kraus VB, 590, 2356
Krause A, 806
Krause I, 1421
Kredich DW, 2330
Kremer JM, 1322
Kriegsmann J, 1517
Krimmel M, 1485
Kristiansen IS, 2293

Kristjansdottir H, 1649
Kronborg G, 2145
Krone W, 574
Krüger M, 2482
Kuchen S, 389
Kuckelkorn U, 697
Kuller LH, 51
Kullmann F, 1594, 2430
Kumagai S, 2612
Kumar V, 2494
Kurien BT, 1017
Kuromaru R, 1298
Kurowska M, 2552
Kurup IV, 555
Kurzik-Dumke U, 210
Kusaka Y, 954
Kuwana M, 275, 465, 1179
Kvien TK, 2293
Kwan O, 828
Kwoh CK, 585, 2496

L

Labarre C, 1056
Lachance L, 483
Lafeber FPJG, 1003, 1025, 1033
Laganà B, 2007
Lahita RG, 455, 1655
Laitko S, 1386
Lajeunesse D, 2112
Lally E, 1194, 2372
Lamas JR, 1975
Lamprecht P, 2507
Lan J-L, 61
Lanchbury JS, 285, 591
Lane NE, 854, 1378
Lang B, 2252
Lange U, 1777
Langevitz P, 1421
Langford CA, 2666
Lanzillo B, 1304
Laroche M, 1093
Larrosa M, 2319
Latchman D, 1783
Lau CC, 1300
Lau CS, 591, 1274
LaValley MP, 1740, 2153
Laxer RM, 2656
Le DT, 2132
Leach M, 189
Lechner S, 1594, 2430
Lecomte F, 2002
Lecouvet FE, 1405
Lederman S, 1291
Lee DR, 703
Lee I-M, 910
Lee J, 1281
Lee S-H, 2085
Lee SK, 2085
Lee SL, 2733
Leech M, 1601
Leflunomide Rheumatoid Arthritis Investigators Group, 1870
Le Goff P, 588, 1062
Lehman TA, 69
Lehmann T, 190
Lehtonen L, 84
Leirisalo-Repo M, 84, 2045
Lenz ME, 1159, 1861
Leong A, 2710
Leow A, 2166, 2430
Lerebours E, 2002
Leu J, 110
Levade M-H, 2002
Levartovsky D, 2561
Levesque H, 2002
Levé-que MC, 569
Levi M, 2471
Levinson JE, 2213
Levy RM, 2309
Levy Y, 1062
Lewis C, 1068
Lhote F, 421
Li C-Y, 812
Li S, 1879
Li Y, 2524
Liang MH, 1087, 1561, 1722
Liao K-K, 61
Lim YS, 1285
Linder R, 574
Lindsley CB, 2213
Lindsley H, 357
Lino-Pérez L, 2160
Liozon E, 2256, 2674
Lipsky JJ, 186
Liu F, 1898
Liu G, 1433
Liu H-G, 641
Liu L, 2039
Livneh A, 1421
Locatelli F, 807
Lock M, 448
Lockshin MD, 1309
Loeser RF, 2103
Lohmander LS, 534
Lohr KM, 1204
López de Castro JA, 1975
López-Larrea C, 1010
López-Soto A, 190, 2257
Loreck D, 806, 1232
Lorenzen I, 918, 2624
Lortholary O, 2674
Lotz M, 2123
Lou C, 25, 861, 2735
Loubet-Lescoulié P, 1093
Loustaud V, 2256
Lovell DJ, 790, 2213
Lu Y, 1558
Luis M, 2160
Lukert BP, 2309
Lundberg I, 1649
Luta G, 2356
Luzina IG, 561
Luzzana C, 1757

M

Ma Y, 1109
Maccario R, 807
Macchioni PL, 1562
Macfarlane GJ, 1397
MacGregor AJ, 366, 1068
Maciel SB, 2494
Mack M, 981
Mackay IR, 2569
Mackus WJM, 1291
MacLeod DL, 2735
Madsen HO, 2145
Maekawa T, 954
Maetzel A, 1870
Magder LS, 2682
Mahfood JP, 2055
Mahomed N, 1722
Mahowald ML, 831
Maier AL, 1322
Maillefert JF, 594
Maini RN, 455, 819, 1779
Makino H, 1508
Maldague B, 1405
Malghem J, 1405
Mallon E, 448
Maloney WJ, 1443
Manfredi AA, 1412
Mange M, 1902
Mangialaio S, 2517
Manicourt D-H, 1159, 1861
Manning AM, 609
Manoliu RA, 2231
Manoussakis MN, 229
Manson JAE, 910
Manzi S, 51, 585, 882
Marcinkiewicz J, 2552
Marfurt J, 187
Marianelli L, 1305
Maricq HR, 306
Marie I, 2002
Marinescu RC, 2139
Marion TN, 2449
Marks AB, 2258
Marolleau J-P, 2275
Marquez M, 1736
Martel-Pelletier J, 157, 710, 1147, 1577, 2112, 2399
Martin MY, 829
Martin RW, 1194, 2372
Martinez-Borra J, 1010
Martinez-Taboada V, 311
Martínez-Taboada VM, 826
Martini A, 807
Marx JJM, 1025
Marzo-Ortega H, 2184
Masi AT, 585
Maśliński W, 2552
Matas-Pericas L, 2489
Mathis D, 2517
Matsen FA III, 1443
Matsuda T, 1609
Matsuki Y, 431
Matsuno H, 669, 1297, 2014
Matsuo H, 1040
Matsuura E, 167, 2461
Matsuyama T, 1609
Matteson EL, 186, 2153
Mattey DL, 2698
Matyas JR, 993
Mauri M, 2260
Maurice MM, 2166, 2430
Mayes M, 1194, 2372
Mazieres B, 475, 1093
Mazzuca SA, 1267
McAbee T, 498
McBeth J, 1397
McCabe D, 498, 1782
McCartney-Francis NL, 1119
McCarty DJ, 585
McCluskey P, 1894
McCluskey RT, 384
McDougal JS, 455
McGonagle D, 1080, 1706, 1998, 2184
McKown KM, 1204
McLaughlin GE, 357
McSweeney PA, 2269
Meadeb J, 799
Medsger TA Jr., 275, 465, 585, 763, 1179, 1194, 2372
Mehta S, 2252
Melchers I, 210
Melfi CA, 1267
Menon R, 1497
Menon S, 735
Merkel PA, 384, 1563
Meroni PL, 197
Merrill JT, 1655
Mertsola J, 2045
Meschia JF, 2243
Métayer J, 2002
Metz C, 1601
Meulenbelt I, 1729
Meyer C, 2011
Meyer O, 1056, 2194
Mezieres M, 2275
Miadonna A, 197
Michel BA, 389, 622
Michel C, 2194
Michet CJ Jr., 46
Michel M, 2194
Michon-Pasturel U, 2674
Mickler EA, 545, 1140
Mier R, 2213
Mierau R, 1552
Migita K, 2440
Mikecz K, 659, 2524
Miller FW, 1285
Miller LA, 248
Milliken ST, 2286
Mills JN, 2543
Mima T, 1635
Min J-K, 2085
Mineau F, 2399
Mineishi S, 2281
Minn A, 1951
Minota S, 1549
Miossec P, 963, 1773
MIRA Trial Group, 1879
Mitsui H, 1917
Miwa Y, 100
Miyakawa S, 1917
Miyake K, 2593
Miyata K, 2577
Mizel DE, 1119
Mizuki N, 1961
Mizushima Y, 443
Moens U, 2449, 2583
Moffa A, 1986
Moirand R, 799
Mok CC, 591, 1274
Moldovan F, 1577
Molloy PJ, 1813

Montagna D, 807
Moore GF, 1691
Moore KD, 2250
Moosig F, 742
Morand EF, 1538, 1601
Moreland LW, 357, 1194, 2372
Morgan SJ, 2060
Morgenstern S, 1421
Mori S, 2616
Morinobu A, 2612
Morishita R, 2532
Morita Y, 1508
Morito F, 2593
Moroldo MB, 1843
Morrell M, 1322
Morris CA, 318
Morris S, 1397
Morrison WB, 1065
Moser KL, 1902
Moskowitz RW, 39, 397
Möttönen T, 84
Moulinier L, 475
Mountz JD, 641
Mountz JM, 641
Moutet F, 2492
Moutsopoulos HM, 229, 1466, 1765
Mu H, 438
Mudgett J, 2074
Muirden KD, 2569
Müller A, 742
Müller CA, 1485
Müller-Ladner U, 490, 1296, 1594, 2430
MULTIVIRC Group, 2204
Múñoz-Gómez J, 2319
Murakawa Y, 291
Murphy FT, 573, 1061
Murray KJ, 1843
Murrell GAC, 2410
Musikic P, 1782
Musliner T, 1246
Muzzonigro T, 1
Myers LK, 1204
Myers R, 1069
Myers SL, 545
Myerscough A, 1617

N

Nagai A, 291
Nagano S, 1644
Nagasawa K, 2593
Nakajima H, 954
Nakamura H, 431, 1917, 2430, 2440
Nakamura S, 1961
Nakamura T, 1609
Nakamura Y, 2616
Nakase T, 2532
Nakashima H, 1644
Nakashima M, 2440
Nakashima-Matsushita N, 1609
Nakashima T, 2440
Nakatsuru S, 2616
Nakazawa F, 2014
Natvig JB, 2471
Nava A, 1347
Navaux F, 1093
Neas BR, 1902
Negishi M, 100
Neidhart M, 389, 622
Nesher G, 2258
Netter P, 1951, 2094
Neudecker I, 1594
Neufang KFR, 574
Nevitt MC, 854, 1246, 1378
Newman J, 299
Newman SP, 735
Nezuka T, 669
Ng S, 818
Nguyen P, 2060
Nicaise P, 1056
Nicolle M, 1040
Nielsen S, 790
Niho Y, 1644
Niiro H, 1644
Nikkari S, 84
Niles JL, 384
Nishihara M, 2616
Nishimura K, 2631
Nishioka K, 519, 686, 1635
Noel E, 475
Noel JC, 1064
Nord E, 2293
Norsworthy P, 1828
Nose M, 2616
Nossent H, 2449
Nourhashemi F, 1093
Nuki G, 1782
Nuss M, 2060
Nuss R, 1550
Nyce K, 2139
Nzeusseu A, 1861

O

Ochi T, 221, 2532
Ochiai N, 1917
Ochs RL, 2123
O'Connor P, 1706
O'Dell JR, 1691
O'Donnell JL, 507
O'Duffy JD, 812
O'Fallon WM, 46, 415
Offenbaecher M, 2482
Ogawa-Shirota Y, 1549
O'Hanlon TP, 1285
Ohashi Y, 2616
Ohgami E, 1644
Ohkuni M, 2577
Ohno S, 1961
Ohsako S, 1833
Ohshima S, 1635
Ohsuzu F, 2255
Ohta A, 2593
Okada S, 1285
Okamoto H, 1508
Okamoto K, 519
Okamoto T, 2430
Okano Y, 275
Okazaki H, 1549
Olaussen E, 2583
Olivi M, 2204
Olivieri I, 1562
Ollier B, 757, 2174
Ollier WER, 1561, 1617, 2698
Olsen BR, 2524
Olson WH, 1370
Onobori M, 1917
Oost WW, 1823
Oostendorp RAB, 1361
Opolon P, 2204
Orces CH, 186
Ordi J, 2260
Oristrell J, 190
Ortel TL, 318, 2250
Osaba M, 2319
Ostbye T, 76
Østergaard M, 918
Ota M, 1961
Otsuka T, 1644
Otto JM, 2524
Overhauser J, 2139

P

Pablos JL, 989, 2733
Pacheco-Tena C, 2160
Pachman LM, 2213
Page G, 963
Pai Y-C, 25
Paikos S, 229
Palermo R, 69
Palmer W, 1691
Pandey JP, 1285
Pando JA, 1889
Pantelidis P, 448
Pap T, 1517
Papadimitriou JC, 561
Pappone N, 1304
Paradela A, 1975
Pardo A, 590
París M, 1908
Park J-H, 2085
Park S-H, 2085
Parsons WJ, 1481
Partridge AJ, 1722
Passo MH, 1843, 2213
Patel P, 1101
Patel SD, 1497
Paulsen G, 1691
Paulsen J, 742
Pavelka K, 1782
Pawlotsky Y, 799
Payne U, 1662
Payton T, 757, 2174
Pearson D, 258
Pearson JD, 631
Pedersen FK, 790
Pelletier J-P, 157, 710, 1147, 1577, 2112, 2399
Perez MD, 2213
Perlemuter G, 1545
Perotti C, 807
Persing DH, 812
Petersen J, 2145
Petri M, 2682
Petronis A, 1228
Petrow P, 1517
Philippe L, 1951
Phillips C, 1722
Picard F, 2275
Pietryla D, 1159
Piette A-M, 2259
Piette J-C, 833, 1062, 1309, 1545, 1560, 2194, 2204, 2259, 2734
Pike MG, 186
Pillemer SR, 1879
Pincus T, 1572, 1797, 2220
Pinède L, 2674
Pisetsky DS, 595
Plachý J, 981
Poilvache P, 1861
Polihronis M, 229, 1466
Pols HAP, 1729
Pompon L, 299
Ponge T, 2674
Pons F, 2319
Poole AR, 39, 129, 527, 534, 2074, 2381
Pope R, 2281
Postlethwaite AE, 1204
Pottier M-A, 2674
Poynard T, 2204
Prahalad S, 1843
Praprotnik S, 831, 1421
Presle N, 2094
Pressman AR, 1378
Prevrhal S, 2497
Price JS, 137, 2390
Price PA, 2624
Procopio E, 1305
Proudman S, 2184
Pucillo LP, 2007
Puéchal X, 824
Pujol J-P, 148

Q

Quinzanini M, 1757

R

Raber H, 1232
Radbruch A, 2039
Rahman A, 1783
Rahman P, 822, 1228
Rairie JE, 51, 882
Rajkumar VS, 930
Ralston SH, 285
Ramsey-Goldman R, 585, 882
Rantakokko K, 84
Ratajczak CA, 2060
Ratnam M, 1609
Rau R, 1782
Rauch J, 1347
Ravaud P, 475, 1556
Ravelli A, 807
Raymond Y, 1347
Raynauld J-P, 1347
Raza K, 182
Reda DJ, 2325
Reece RJ, 1481
Reed AM, 2213, 2330
Reichlin M, 69, 2728
Reinhold-Keller E, 751
Rekvig OP, 2449, 2583
Rennebohm RM, 2213
Renner JB, 2356
Rescigno M, 1412

Resendiz M, 2189
Reveille JD, 268
Rezaian MM, 1779
Ricciardi-Castagnoli P, 1412
Richmond RS, 2103
Rider LG, 1285, 2213
Ridgway J, 1706
Riemekasten G, 196
Rigby SP, 448
Rijkmans J, 2231
Rijnders AWM, 1497
Rijpkema SGT, 1473
Rivas LJ, 1908
Robbins PD, 1, 490
Robert J, 1051
Roberts CR, 490
Roberts WN, 357
Roberts-Thomson P, 1068
Robinson CJG, 1168
Roblot P, 2674
Roby P, 1617
Roccaforte S, 2689
Rodríguez MA, 1908
Rodriguez-Pardo D, 2489
Rodriguez Pérez A, 1010
Rodríguez-Valverde V, 826
Roldán JF, 2498
Romero FI, 2606
Roncal F, 1975
Rooney TW, 357
Roosendaal G, 1025, 1033
Roqué M, 2319
Rosen S, 2281
Rosenbaum JT, 825
Rosenbaum R, 825
Rosenberg LC, 527
Ross PD, 1246
Roth SH, 2153
Rothfield NF, 455
Rothschild B, 357
Roubey RAS, 318
Rovere P, 1412
Rowley MJ, 2569
Rozman B, 1782
Rubin K, 930
Rudd PM, 1682
Rudwaleit M, 832, 2039
Ruffin DM, 1736
Rumold R, 2132
Russell AS, 2021
Rutz S, 240
Ryan LM, 555
Rzepka R, 210

S

Saaibi DL, 1889
Saal JG, 1485
Sabbadini MG, 1412
Sack M, 357
Saeki Y, 1635
Saha N, 1577
Said G, 824
Sakai H, 2440
Sakai K, 1298
Sakane T, 2418
Salazar S, 1908
Saleeb S, 2335
Sali A, 1986
Salmon D, 1062
Salmon JE, 818, 1655
Salvarani C, 1259, 1562
Sambrook PN, 366
Sammaritano LR, 1655
Sanchez Del Río J, 1010
Sanchez-Sitjes L, 2489
Sandborn WJ, 186
Sandell LJ, 1443
Sandino S, 2189
Sandrock D, 1232
Sanmartí R, 2319
Sano H, 954
Sano K, 1986
Santiago B, 989
Santiago V, 2189
Sany J, 678
Saraux A, 588, 1062
Sasai M, 1635
Sasaki Y, 1298
Sasazuki T, 2577
Sato H, 1549
Savage COS, 631, 2019
Sawada K-I, 167
Sawada T, 1655
Saxne T, 39
Schaible T, 1779
Schanberg LE, 2330
Schattenkirchner M, 981
Scheepers RHM, 1823
Scheffler S, 697
Scheinberg MA, 2494
Schentag CT, 822, 1228
Schick C, 210
Schifferli JA, 187
Schikler KN, 2213
Schiwy-Bochat K-H, 1936
Schlöndorff D, 981
Schnabel A, 742, 1752
Schnarr S, 2736
Schnitzer TJ, 1370
Schölmerich J, 1594
Scholze J, 578
Schouls LM, 1473, 2198
Schroeder J, 2281
Schuening F, 2281
Schultz H, 2303
Schumacher HR Jr., 1281, 1696, 1889, 2153
Schumann F, 971
Schur P, 1087
Schwarcz R, 110
Scieux C, 942
Scofield RH, 199, 1017
Scorza R, 1757
Scott DGI, 1339
Scott JC, 854, 1378
Sebba AI, 357
Sebesta DS, 769
Seibold JR, 1194, 2372
Seitz M, 190
Seki H, 2532
Seki N, 2577
Seldin MF, 318, 1071
Sell S, 1485
Selman M, 590
Selva-O'Callaghan A, 2489
Selzer F, 51
Semana G, 1062
Senécal J-L, 1307, 1347
Sennello G, 498
Serrano de la Peña L, 2139
Serrano L, 989
Sewell KL, 2309
Seyer JM, 1204
Seyfert C, 1517
Sgonc R, 581
Shamim E, 1285
Shanahan EM, 2724
Sharma L, 25, 33, 861, 2735
Sharp GC, 190, 899
Shepherd JA, 2497
Sherry DD, 2330
Shi M, 659
Shi Y, 948, 1088
Shinozaki M, 1644
Shirazi I, 2561
Shi-Wen X, 299
Shlopov BV, 719
Shoenfeld Y, 1062, 1421
Shoeps P, 2482
Siamopoulou A, 373
Sibbitt RR, 2026
Sibbitt WL Jr., 2026
Sieberer C, 581
Siebertz B, 1936
Siegert S, 2039
Sieper J, 196, 1386, 2039
Sigal LH, 1809
Sillibourne J, 1101
Silman AJ, 299, 757, 1219, 1339, 1397, 1617, 2174, 2660
Silverman ED, 1354, 2346
Simmons WJ, 110
Simms RW, 1740, 2638
Singer II, 1128, 2074
Singh LM, 1553
Siraj QH, 819
Sison C, 1655
Sitarz A, 1833
Sivri A, 827
Slagboom PE, 1729
Sledge CB, 1722
Sluiter WJ, 1823
Smeenk R, 455
Smeets TJM, 650, 948
Smith D II, 1696
Smith GN Jr., 545, 719, 1140
Smith H, 318
Smith MD, 1068, 1601, 2213
Smith R, 2646
Smith S, 728
Smith TF, 1255
Smolen JS, 193, 455
Smyth CA, 641
Snaith M, 189
Sneller MC, 2666
Snieder H, 1068
Snowden JA, 2286
Sobao Y, 175
Solans-Laque R, 2489
Solchaga LA, 2631
Somes GW, 1204
Sommer S, 1998
Sønderstrup G, 1497
Song GG, 818
Song X-Y, 1119
Song YW, 1285, 1528
Sonneborn DR, 2710
Sörensen H, 1386
Sorgi ML, 2007
Sowers MF, 483, 2497
Spack E, 1040
Spector TD, 17, 285, 366, 1068
Speechley M, 76
Spiller I, 2039
Stafford HA, 69
Stampacchia G, 2249
Stangassinger M, 981
Stanson A, 311
Steen V, 1194, 2372
Steen VD, 763
Steere AC, 1813, 2705
Steere EL, 1204
Štefanec T, 2491
Stefka J, 2281
Stegeman CA, 1823, 2495
Steidle M, 1485
Stein CM, 1572
Stein LD, 2330
Steindorf K, 751
Steiner G, 193
Steinfeld S, 1064
Steinsson K, 1649
Stekman IL, 1908
Sterry W, 240
Stiehl P, 1517
Stockman A, 2569
Stokes DG, 1433
Stoltenberg M, 918, 2624
Stone JH, 2365
Stoop R, 2074, 2381
Storrer CE, 561
Strand V, 1322, 1870
Studer RK, 248
Study of Osteoporotic Fractures Research Group, 854, 1378
Stuhlmüller B, 971
Suemura M, 1635
Sugai S, 2612
Sugamoto K, 221
Sugimoto H, 1549
Sugiura T, 291
Sukenik S, 1066
Sumida T, 519, 1917
Summers KL, 507
Sun J-B, 1628
Sunahara N, 1609
Sundberg C, 930
Sunku J, 46
Sutton-Tyrrell K, 51
Suzuki H, 1917
Suzuki K, 431, 2255
Suzuki N, 2418, 2593
Suzuki R, 221
Svejgaard A, 2145
Swearingen C, 2220
Swen WAA, 2231
Symmons DPM, 757, 1339, 2174
Szodoray P, 1673

Szondy Z, 1673
Sztein MB, 561

T

Taccetti G, 1305
Tada Y, 2593
Tailor H, 90
Tait BD, 2569
Tak PP, 650, 948, 1473, 2198, 2430
Takabayashi A, 1298
Takahashi K, 2123
Takamizawa-Matsumoto M, 431
Takano H, 221
Takasaki Y, 455
Takeba Y, 2418
Takeuchi E, 221, 2532
Takiguchi M, 175
Talar-Williams C, 2666
Talken BL, 703
Tamaki K, 328
Tan EM, 455, 2021
Tan FK, 2656
Tanaka T, 1635
Tanaka Y, 1644
Tanzer M, 1722
Tapinos NI, 1466
Tardif G, 1147, 1577
Targoff IN, 1285
Tarkowski A, 1628
Tatsis E, 751
Tatsuzawa O, 2577
Tavernier C, 594
Tavoni A, 2249
Taylor P, 448
Taylor-Albert E, 69
Tebib J, 1773
Tedeschi A, 197
Teichmann J, 1777
TeKoppele JM, 1003, 1033
Tengnér P, 2471
Terada M, 2616
Terkeltaub R, 1986
Terlain B, 1951, 2094
Tervaert JWC, 384, 1823
Theodoridis E, 1828
Thiagarajan P, 268, 1189
Thiel T, 318
Thomas DW, 1291
Thomas P, 475
Thompson A, 1870
Thompson D, 1246
Thompson KM, 2471
Thomson G, 438
Thomson W, 757, 2174
Thonar EJ-MA, 1159, 1861
Thorbecke GJ, 110
Thornton S, 1109
Thumboo J, 46
Tijssen H, 1621
Till SH, 2390
Tilley BC, 1879
Tinahones FJ, 2606
Tincani A, 1412
Toivanen P, 84
Tokuhira M, 1927
Tokunaga K, 175
Tomita N, 2532
Tomita T, 221, 2532
Tomšič M, 831
Tony H-P, 2303
Torre-Alonso JC, 1010
Toubi E, 1833
Tournier-Lasserve E, 2194
Toyosaki-Maeda T, 221
Toyoshima S, 593
Trabandt A, 742
Tracy RP, 51
Traynor A, 2281
Trendelenburg M, 187
Trentham DE, 587
Triantaphyllopoulos KA, 90
Triplett DA, 167, 1309
Trucco M, 1497
Trupin LS, 769
Tsao B, 2601
Tselepis AD, 373
Tsuchida T, 328
Tsuchiya N, 175
Tsukano M, 1609
Tsutsumi A, 2461, 2727
Tuan RS, 1433
Tugwell P, 1870
Tuke PW, 2492
Turchini S, 1305
Tyndall A, 187

U

Ueda K, 2577
Uhlig K, 981
Uksila J, 1386
Ulrich-Merzenich G, 1553
Uramoto KM, 46
Urayama S, 2440
Urbano-Márquez A, 190, 1051, 2257
Uriarte E, 826
Ushiyama O, 2593
Uthman I, 1347
Utley M, 1557
Uziel Y, 2656

V

Vaingankar S, 1986
Vaishnaw AK, 1833
Vakkalanka RK, 871
Valencia-Flores M, 2189
Valencia X, 2189
Valeriano J, 2055
Valkenburg HA, 1729
Vallance JKH, 2735
Vallinoto C, 1412
van Baar ME, 1361
Vande Berg BC, 1405
van de Leur E, 1936
van den Berg HM, 1025, 1033
van den Berg WB, 1128, 2074, 2381
van de Putte LBA, 1621
van der Graaff WL, 2166
van der Heijden IM, 1473, 2198
van der Kraan P, 2074
van der Kraan PM, 2381
van der Pol WL, 1823
van der Voort EAM, 2430
van de Winkel JGJ, 1823
van Duijn CM, 1729
van Egeren A, 1861
van Elderen C, 1621
van Embden JDA, 1473
van Lent P, 2074
van Lent PLEM, 1128
van Lier RAW, 650, 2166
van Meurs JBJ, 1128, 2074
van Riel PLCM, 1621
van Venrooij WJ, 455
van Zeben D, 1854
Varga J, 1194, 2372
Vasey FB, 2055
Vázquez-Mellado J, 2160
Veale D, 1998
Veale DJ, 1481
Velez FF, 1784
Velins S, 2524
Venables PJW, 448, 819, 2493, 2732
Verbruggen G, 1067
Verheijden GF, 1497
Verma M, 1894
Versendaal J, 2430
Verwaerde C, 678
Verweij CL, 2166, 2430
Verzijl N, 1003
Veys EM, 1067
Vianen ME, 1025, 1033
Viard J-P, 1062
Vicario JL, 989
Vidal E, 2256
Vije AEM, 2198
Vilardell M, 2260
Vilardell-Tarrés M, 2489
Vilaseca J, 190
Vilim V, 2356
Viola S, 807
Virtala M, 84
Vischer TL, 942
Vitali C, 2249
Volin MV, 1927
Voulgarelis M, 1765

W

Wagner S, 1485
Wahl CL, 1119
Wahl SM, 1119
Wahren-Herlenius M, 2471
Wakefield D, 1894
Wakefield R, 1706, 2184
Waldmann H, 1998
Wali JP, 824
Wallace DJ, 2021, 2255
Wallach S, 2309
Walport MJ, 1828
Wang GC, 742
Wang GS, 899
Wang MX, 2410
Wang Q, 2055
Wang-Weigand S, 137
Wanke LA, 1209
Ward FE, 569
Ward MM, 338, 409, 780, 891
Ward R, 1071
Wasko MC, 1
Watson M, 1682
Watt I, 1782
Watts RA, 2497
Wazières B, 2674
Weaver A, 1691
Webster EA, 1291
Wechsler B, 1545
Weedon H, 1601
Wees S, 1691
Wehling M, 395
Wehrli R, 622
Wei AQ, 2410
Weinberg JB, 569
Weinblatt ME, 1322
Weiner S, 1194, 2372
Weinrach D, 861, 2735
Weinstein A, 1194, 2372
Weisman MH, 357, 1194, 2153, 2372
Weiss RA, 448
Weksler B, 1421
Welch KE, 357
Welles C, 2281
Wells G, 1870
Wernicke D, 1517
Wessinghage D, 1594
West SG, 2269
Westhoff CS, 1517
Weyand CM, 311, 589, 844, 2258
White B, 595, 1168, 1194, 2372
White KP, 76
Whiting-O'Keefe QE, 2365
Wick G, 581
Wigley FM, 1168, 1194, 2372
Wiik A, 455
Wilbrink B, 1473, 2198
Wilckens T, 393
Wilcox DM, 2060
Wilder RL, 954, 1696
Wiles N, 757, 1339, 2174
Willcox N, 1040
Willems WJ, 2231
Williams B, 1782
Williams CJ, 2139
Williams EN, 854
Williams JM, 1159
Williams R, 1655
Williams RJ, 2410
Williams RO, 90
Williamson EE, 2243
Wilson H, 299
Wilson M, 455
Wilson PWF, 306
Wilson WA, 396, 1309
Wise R, 1168
Wishaupt JO, 650
Witte RJ, 2243
Wittke F, 2194
Wolf KJ, 1232
Wolfe F, 1797, 2220
Wolfson-Reichlin M, 69, 2728
Wong RWS, 1274
Wong W-K, 1194, 2372
Woo C, 871

Woo P, 590, 1101, 2017
Woodford-Richens KL, 285
Woods JM, 1927
Woods VL Jr., 2132
Wordsworth P, 1040
Worthington J, 1617
Wright TM, 275, 465, 1179, 1451
Wu J, 2601
Wu Q, 641
Wuorela M, 2045

X

Xanthou G, 229

Y

Yabuki K, 1961
Yamada H, 2727
Yamamoto K, 2532
Yamamoto T, 2719
Yamamura M, 1508
Yamaoka K, 1644
Yamasaki S, 2440
Yamazaki J, 100
Yang Y, 1538
Yarboro C, 1696
Yaron I, 2561
Yaron M, 2561
Yelin EH, 769, 1209, 2710
Yin Z, 2039
Yocum D, 357
Yodoi J, 2430
Yokota S, 2577
Yonezawa T, 2014
Yoo D-H, 818
Yoo JU, 2631
Yoo W-H, 2085
Yoshida S, 2430
Yoshino S, 1917
Yoshio T, 1549
Yoshizaki K, 1635
Youinou P, 588, 1062
Youn J, 2085
Young A, 1557
Yu H, 1902
Yu S, 1609
Yudoh K, 669, 1297, 2014
Yurovsky VV, 1168

Z

Zacher J, 1485, 1517
Zak M, 790
Zecca M, 807
Zeher M, 1673
Zeidler H, 2736
Zemel LS, 1833, 2213
Zhang H, 1662
Zhang M, 157
Zhang Y, 33, 306, 527
Zhao Y, 2132
Zhao Y-X, 1662
Zhou D, 2132
Zhu M, 2132
Zhu Y, 1443
Zhuang S, 948
Zinn KR, 641
Zizic TM, 2309
Zompi S, 2275
Zonana-Nacach A, 2682
Zorzin LR, 2007
Zvaifler NJ, 948
Zwinderman AH, 1854

SUBJECT INDEX

Arthritis & Rheumatism, Volume 42, Number 1–12, 1999

A

Abortion, IgA-class anti–β_2-glycoprotein I antibodies and unexplained spontaneous recurrent, 2727
ACR 20, as clinical measure, 1572, 1781
Acute pyrophosphate arthritis. *See* Pseudogout
ADAM-15, mRNA up-regulation in OA and normal cartilage, 1946
Adhesion molecules
  anti–endothelial cell antibodies in systemic vasculitis and SLE, 631
  chemotaxis in endothelial cells in RA and soluble, 1927
  in RA nodules and synovial tissue, 1067
  in Takayasu arteritis, 1421
Adjuvant arthritis
  MRI in rat, 2060
  ^{99m}Tc-labeled E-selectin–binding peptide in rat, 641
  sustained IL-1Ra blood levels in, 498
Adolescents, EBV as risk factor for SLE in children and, 1782
Adrenomedullin, in RA, 1297
Age, nonenzymatic glycation and proteoglycan synthesis of chondrocytes and, 1003
Aggrecan
  collagen damage initiation and, 2074
  immune response to link protein and G1 domain in OA, 527
  progressive imbalance in OA of collagen and, 993
  turnover in OA, 534
Aggrecanase, epitopes in mouse arthritis, 1128
Alendronate, bone density changes and fracture risk in OA, 1246
Alleles
  age-specific effects of JRA-associated HLA, 1843
  anti–β_2-glycoproteins and HLA class II, 268
  differential function of HLA-DRB4*0401 and HLA-DRB4*0402 in RA, 1497
  early synovitis associated with HLA, 1696
  ethnic differences in SSc and HLA-DRB1, 465
  HLA-DQ, in RA, 1621
  HLA-DRB1, in inflammatory polyarthritis, 757
  HLA-DRB1 and RF influence on outcome of RA, 2174
  IFN-β-1a–induced arthritis with HLA-DRB1*0404 allele, 569
  Mexican Americans and HLA-DRB1, 1329
  MICA-A9 allele and susceptibility to psoriatic arthritis, 1010
  MIC-A association with Behçet's disease, 1961
  poly(ADP-ribose) polymerase and susceptibility to SLE or antiphospholipid syndrome, 2194
  type II collagen antibodies in RA and HLA, 2569
α_1-antitrypsin, induction by IL-6–type cytokines in joints, 1936
American College of Rheumatology (ACR)
  ACR 20 as a clinical measure, 1572, 1781
  nomenclature for neuropsychiatric SLE, 599
  presidential address, 406
  rheumatology training and, 595
5-aminosalicylic acid, chemotaxis inhibition in endothelial cells in RA and, 1927
Amitriptyline, inhibitory effects in synovial cells, 2561
Amyloidosis, cystic fibrosis and, 1563
Angiitis, primary, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy versus, 2243
Angiogenesis, in RA, 622
Animal models. *See specific animals*
Ankylosing spondylitis (AS)
  bone mass loss in early, active, 2319
  peptide specificity of B*2705, B*2704, and B*2706 in, 1975
  thalidomide in treatment of refractory, 580
Annexin I, inhibition in rat adjuvant arthritis synovial tissue, 1538
Anterior cruciate ligament, collagen type II degradation following rupture of, 2390
Anti–β_2-glycoprotein I antibodies
  chimeric antibody for anticardiolipin antibody assay standard, 2461
  dendritic cells and, 1412
  IgA-class, and unexplained spontaneous recurrent abortion, 2727
Anti–β_2-glycoproteins, HLA class II and, 268
Antibiotics. *See also names of specific antibiotics*
  resistance, in Lyme disease, 2705
Antibodies/autoantibodies. *See names of specific antibodies*
Anticardiolipin antibodies
  chimeric antibody as assay standard for, 2461
  cognitive function in SLE and, 728, 735
  IgA-class anti–β_2-glycoprotein I antibodies and unexplained spontaneous recurrent abortion, 2727
  protein C inhibition and, 167
Anti-C1q antibodies, in SLE, 1828
Anti-DNA topoisomerase I antibodies, ethnic differences in SSc and, 465
Anti–endothelial cell antibodies
  modification of endothelial cell function, 631
  in Takayasu arteritis, 1421
Antigen-induced arthritis, high-resolution 3-D MRI in, 119
Antigens
  dermatomyositis and Mi-2, 1552
  DNA and antibodies to polyomavirus T antigen, 2583
  polyomavirus T antigen termination of histone-specific T cells anergy, 2449
Anti–52-kd Ro/SSA antibodies, diffuse infiltrative lymphocytosis syndrome and type 1 HIV with, 578
Anti–lamin B1, in SLE, 1347
Antineutrophil cytoplasmic antibodies (ANCA)
  cystic fibrosis and, 1305
  microscopic polyangiitis and, 421
  Wegener's granulomatosis associated with alternating, 384, 2494
Antinuclear antibodies (ANA)
  enzyme immunoassays evaluation for, 455, 2021
  fine specificity of antibody binding to Ro/SSA and La/SSB ribonucleoproteins, 199
  IL-10 in SLE and, 1649
Antiphospholipid antibodies
  IgA-class anti–β_2-glycoprotein I antibodies and unexplained spontaneous recurrent abortion, 2727
  production in SLE and environmental factors, 1062
  sequence features of monoclonal, 1783
  thromboxane biosynthesis in SLE and, 2689
  with Wegener's granulomatosis and polyarteritis nodosa, 2250
Antiphospholipid syndrome
  anti–β_2-glycoproteins and HLA class II alleles, 268
  antiprothrombin antibodies and coagulation in primary, 2132
  autoantibodies against malondialdehyde-modified lipoprotein(a) in, 2606
  chimeric antibody as assay standard for anticardiolipin antibodies, 2461
  criteria for, 1309
  genetic basis of, 318
  poly(ADP-ribose) polymerase alleles and susceptibility to SLE or, 2194
  polymorphism of β_2-glycoprotein I in, 1189, 1655
  typhoid fever and SLE-associated catastrophic, 1056
Antiproteasomal antibodies, in primary SS, 697
Antiprothrombin antibodies, coagulation in primary antiphospholipid syndrome and, 2132

Antiribosomal P antibodies
in juvenile-onset SLE, 69
in lupus nephritis, 2729
role of carrier protein in immunosorbent assay for, 593
Anti-RNA polymerase antibodies, SSc and, 275
Anti-Ro 52-kd monoclonal antibodies, in SS, 2471
Anti-Ro/La antibodies, in congenital complete heart block, 1757
Anti-snRNP autoantibodies, in MCTD, 899
Anti-SSA/Ro antibodies
in congenital complete heart block, 1757
ethnic differences in SSc and, 465
induced in mice, 1017
Anti–tumor necrosis factor α, immunotherapy in pityriasis rubra pilaris and inflammatory arthritis, 1998
Apheresis
filtration, in RA, 431
Prosorba column treatments for refractory RA, 2153
RA and, 2255
Apolipoprotein H. *See* β_2-glycoprotein I
Apolipoproteins
in active JRA, 373
RA and serum lipoproteins and, 443
Apoptosis
antigen sources for dendritic cells and, 1412
of CD4+ T cells and disease activity in SS, 1673
c-*myc* oligonucleotides in RA and, 954
defects with CD95 mutations, 1833
Fas/Fas ligand–mediated in synoviocytes, tumor necrosis factor α and, 519
induction by proteasome inhibitor, 2440
inflammatory myopathies and Fas/Fas ligand, 291
lack of endothelial cell, in mouse SSc, 581
nitric oxide production and, in the meniscus in OA in rabbit models, 2123
RA and chondrocyte, 1528
in scleroderma, 2491
Atherosclerosis
carotid plaque in SLE and, 51
in RA, lipoproteins and, 2491
Autoantibodies. *See names of specific autoantibodies*
Autosplenectomy, in SLE, 1307
Avocado/soybean unsaponifiables, articular chondrocyte expression of transforming growth factors and, 148
Ayurveda, rheumatic diseases in, 1553
Azathioprine, in RA, 186

B

Bacterial DNA, detection in septic arthritis, 2198
Bax promoter activity, dominant-negative p53 mutations in RA and, 1088
B cells
CD40 in SLE, 871
Ig gene transcripts in SS and, 240
in SLE, 2593
Bcl-2, in RA, 1528
Behçet's disease
HLA-B51 and MHC class I and, 1961
Th1 and immune response in, 1967
β_2-glycoprotein I
in antiphospholipid syndrome, 2461
polymorphism in antiphospholipid syndrome, 1655
polymorphisms in, 1189
protein C inhibition and monoclonal anticardiolipin antibodies, 167
Bisphosphonate, corticosteroid-induced osteoporosis and, 1736
Bland-Altman analysis versus correlation analysis, 1556, 1557
Bone densitometry, in adults with history of juvenile chronic arthritis, 790
Bone marrow transplantation, SLE and long-term remission with allogenic, 1777
Bone mineral density (BMD)
alendronate and fracture risk in OA, 1246
bone loss and fracture risk in OA, 1378
bone mass loss in early, active AS, 2319
menopause and incidence of OA, 483, 2497
risedronate in prevention of steroid-induced bone loss, 2309
type I collagen polymorphisms and, 285
Borrelia burgdorferi, in Lyme arthritis, 1473, 1809, 1813, 2705
B7 proteins, expression by salivary gland epithelial cells in SS, 229
British Isles Lupus Assessment Group Index, 1354
Bronchoalveolar cells, in SSc lung disease, 1168

C

Calcitonin, in canine OA, 1159
Calcitonin gene-related peptide modulation of RA synovial cell function, 2418
Calcium pyrophosphate dihydrate (CPPD)
arthritis and hyaluronan, 1302
chromosome mapping of human cartilage intermediate layer protein in deposition syndromes, 2139
signaling pathways in chondrocytes and, 555
Canine models
blood-induced joint damage, 1033
calcitonin in OA, 1159
diacerhein in OA in, 545
Cardiovascular disease
carotid plaque in SLE and, 51
morbidity in SLE and, 338
in RA, lipoproteins and, 2491
Cartilage
Metargidin mRNA up-regulation in OA and normal, 1946
nitric oxide synthase inhibitor protection of, 2094
Cartilage destruction
blood-induced joint damage, 1025, 1033
collagen, type II degradation following anterior cruciate ligament rupture, 2390
collagen destruction in goat joints and oncostatin M, 2543
matrix metalloproteinase inhibitors and cartilage breakdown in OA, 129
neurogenically induced damage in, 1951
retinoic acid–induced degradation of type II collagen, 137
Cartilage intermediate layer protein, chromosome mapping of human, in CPPD deposition syndromes, 2139
Cartilage oligomeric matrix protein
levels in OA, 2356
serum markers in familial OA, 39
Caspase
in OA, 1577
tumor necrosis factor α and Fas-mediated apoptosis in synoviocytes, 519
Cathepsin K mRNA, in OA synovial giant cells, 1588
CCR5
chemokine receptor in synovial effusions, 981
in RA, 989
CD4
apoptosis and disease activity in SS, 1673
differential function of HLA-DRB4*0401 and HLA-DRB4*0402 in RA, 1497
Fas/Fas ligand and apoptosis in inflammatory myopathies, 291
monoclonal anti-tumor necrosis factor α and Th1 CD4+ T cells in RA, 2166
CD8
inflammatory myopathies and Fas/Fas ligand–induced apoptosis, 291

CD8 *(cont'd)*
modulation of oral tolerance to type II collagen by cytokines and, 110
in SSc lung disease, 1168
CD14, *Salmonella*-triggered reactive arthritis, modulation of peripheral blood mononuclear cell activation in, 2045
CD40
in hyper-IgM syndrome, 1291
in SLE, 871
CD44, joint inflammation and, 659
CD55, expression in RA, 650
CD68, YKL-40 in giant cells, 2624
CD80, transforming growth factor β and dendritic cells in RA, 507
CD86, transforming growth factor β and dendritic cells in RA, 507
CD95, apoptotic defects in SLE with mutations of, 1833
CD97, expression in RA, 650
CD146, in RA synovial fluid, 622
CD40-CD154, RA synovial cell production of IL-12 and, 1917
CD154, in hyper-IgM syndrome, 1291
CDR3, usage among Sm-B–specific T cell clones, 703
Cerebral autosomal dominant arteriopathy, with subcortical infarcts and leukoencephalopathy versus primary angiitis of the central nervous system, 2243
Cerebrovascular accidents
blindness in giant cell (temporal) arteritis and, 825
morbidity in SLE and, 338
Chemokines
in collagen-induced arthritis, 1109
receptor CCR5 in RA, 989
receptor CCR5 in synovial effusions, 981
Chemotaxis, inhibition by sulfasalazine in RA endothelial cells, 1927
Chiari malformation, in fibromyalgia, 2731
Childhood Myositis Assessment Scale, 2213
Children. *See also entries beginning with* "Juvenile"
EBV as risk factor for SLE in adolescents and, 1782
hemophilia and femoral head osteonecrosis in, 1550
Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in SLE in, 1354
thrombotic thrombocytopenic purpura and SLE in, 2346
Chingford Study, 17
Chlamydia pneumoniae, in arthritis synovial tissue, 1889
Chlamydia trachomatis
antibodies in reactive arthritis, 942
in arthritis synovial tissue, 1889
nucleic acids in asymptomatic subjects, 1281
in reactive arthritis, 1386
Cholera toxin-type II collagen conjugate vaccine in murine collagen-induced arthritis, 1628
Chondrocytes
α_1-antitrypsin induction by IL-6 in, 1936
apoptosis in RA, 1528
collagenase 3 production by human OA, 1147
collagenase regulation in human, 719
nitric oxide inhibition of transforming growth factor β production by, 248
nitric oxide production regulation by IL-17 in osteoarthritic, 2399
nonenzymatic glycation and proteoglycan synthesis of, 1003
plasma cell glycoprotein-1 and B10 in inorganic pyrophosphate metabolism in, 1986
purine receptor expression in articular, 258
signaling pathways of inorganic pyrophosphate in, 555
stable transfection of human fetal, 1433
transforming growth factor β, avocado/soybean unsaponifiables and articular expression in, 148
Chondrogenesis, chondroprogenitor cells of synovial tissue and, 2631
Chromosome 1q41, linkage with SLE, 1902
Ciprofloxacin
in reactive arthritis, 1386
in reactive arthritis and anterior uveitis, 1894
Clinical trials
ACR 20 as a clinical measure and, 1572, 1781
joint lavage and steroid injection in knee OA, 475
Clones, T cell receptors usage among Sm-B–specific T cell, 703
c-*myc* oligonucleotides, in RA, 954
Cognitive function, in SLE, anticardiolipin antibodies and, 728, 735
Collagenase 1, inhibition by doxycycline, 1140
Collagenase 2, inhibition by doxycycline, 1140
Collagenase 3
inhibition by doxycycline, 1140
production by human OA chondrocytes, 1147
in RA, 1517
Collagen-induced arthritis
cytokine expression during, 1109
IFNβ gene therapy in murine, 90
in IL-6-deficient mice, 1635
IL-12 regulation of murine, 100
nuclear factor κB decoy transfer for, 2532
sustained IL-1Ra blood levels in, 498
type II collagen–cholera toxoid conjugate vaccine in murine, 1628
Collagen type I, osteoporosis and polymorphism in, 285
Collagen type II
–cholera toxoid conjugate vaccine in murine collagen-induced arthritis, 1628
collagen damage initiation and, 2074
degradation during murine OA, 2381
degradation following anterior cruciate ligament rupture, 2390
doxycycline and, 1140
HLA alleles in RA and, 2569
procollagen in OA, 1443
progressive imbalance in OA of aggrecan and, 993
RA and T cell response to, 2085
RA treatment with oral bovine, 1204
retinoic acid–induced degradation of, 137
serum markers in familial OA, 39
stable transfection of human fetal chondrocytes with, 1433
treatment of RA, 585
Combination therapy, MTX and leflunomide in RA, 1322, 1870
Complement
SLE and, 2023
SLE and C1q antibodies, 187
Congenital complete heart block
fluorinated glucocorticoids and, 2335
maternal HLA phenotype and, 1757
Connective tissue disease. *See also* Mixed connective tissue disease (MCTD)
intestinal pseudoobstruction and octreotide in, 1545
long-term outcome in mixed, 899
Pneumocystis carinii pneumonia in, 780
T cell receptors usage among Sm-B–specific T cell clones in, 703
Correlation analysis versus Bland-Altman analysis, 1556, 1557
Corticosteroids. *See also* Steroids
fracture frequency in SLE and, 882
-induced osteoporosis, prevention of, 1736
-induced osteoporosis and vitamin D, 1740
risedronate in prevention of steroid-induced bone loss, 2309
Cortivazol, joint lavage and steroid injection in knee OA, 475
Cost-effectiveness studies
in OA, 1267
in RA, 347, 1209, 2293
Coxarthrosis, subchondral insufficiency fractures of femoral head, 2719
Cryoglobulinemia
hepatitis C virus in type II, 1898

Cryoglobulinemia *(cont'd)*
IFNα anti-angiogenic activity with hepatitis C virus and, 1051
in vasculitis, 2507
Cyclooxygenase 2, inhibitors and glucocorticoid receptors, 157
Cyclophosphamide
autologous blood stem cell rescue in severe RA and, 2286
hematopoietic stem cell mobilization in refractory RA, and granulocyte colony-stimulating factor administration, 2275
-induced neutropenia in Wegener's granulomatosis, recombinant human granulocyte colony-stimulating factor in treatment of, 1752
intravenous pulse versus oral, 2019
localized bowel vasculitis and postoperative, 182
ovarian failure and SLE flares due to, 1274
in staged approach in treatment of Wegener's granulomatosis, 2666
CYP19, locus in RA, 1617
Cystic fibrosis
autoantibodies against bactericidal/permeability protein in, 1305
rheumatic disease and, 1563
Cytokines. *See also entries beginning with* "interferon"; *entries beginning with* "interleukin"
in collagen-induced arthritis, 1109
gene transfer of inhibitors of, 490
inhibition of tumor necrosis factor α–induced prostaglandin E_2 by, 710
modulation of oral tolerance to type II collagen by, 110
in RA and synovial tissue, 1067
in reactive arthritis, 2039
Salmonella-triggered reactive arthritis, modulation of peripheral blood mononuclear cell activation in, 2045
SSc and type 2, 1168
taurine chloramine inhibitory function in RA synoviocytes and, 2552
in Wegener's granulomatosis, 742
Cytomegalovirus, antibodies in SSc, 389
Cytotoxicity, in RA, 954

D

Δ32CCR5, RA and, 2732
Dendritic cells
opsonized apoptotic cells as antigen source for, 1412
transforming growth factor β influence on, 507
Dermatomyositis, Mi-2 antigen and, 1552
Dexamethasone
annexin I inhibition in rat adjuvant arthritis synovial tissue and, 1538
macrophage migration inhibitory factor in RA and, 1601
Diabetes, neuropathic arthropathy, 806
Diacerhein, in canine OA, 545
Diclofenac, misoprostol cost effectiveness in RA and, 2293
Diffuse infiltrative lymphocytosis syndrome, with anti–52-kd Ro/SSA and type 1 HIV, 578
Dimaprit, modulation of oral tolerance to type II collagen by cytokines and, 110
Disability
function and, in fibromyalgia, 76
musculoskeletal disorders, prevalence in US, and, 769
process in RA, 1712
Disability Index, of HAQ, 2372
Disc degeneration, MRI study in twins, 366
Disease-modifying antirheumatic drugs (DMARDs)
drug resistance in RA and, 2014
in early RA, 1691
radiographic progression in RA and, 1066
DNA
antibodies to polyomavirus T antigen and, 2583
anti-DNA topoisomerase I antibodies and ethnic differences in SSc, 465
bacterial, detection in septic arthritis, 2198
Doxycycline
collagenase regulation in OA by, 719
matrix metalloproteinase inhibition by, 1140
SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis) response to, 819
D-penicillamine, high-dose vs. low-dose in early diffuse SSc, 1194

E

Endothelial cells, chemotaxis inhibition by sulfasalazine, 1927
Environmental factors, antiphospholipid antibody production in SLE and, 1062
Enzyme immunoassays, evaluation for ANA, 455, 2021
Epidemiology, of RA, 415
Epitopes
aggrecanase and metalloproteinase, 1128
anti–Ro 52-kd monoclonal antibodies in SS and, 2471
Chlamydia trachomatis antibodies in reactive arthritis and, 942
differential function of HLA-DRB4*0401 and HLA-DRB4*0402 in RA, 1497
EBV, HLA-DR4, and risk of RA, 1485
in peptide-induced anti-Ro in mice, 1017
shared, early synovitis and, 1696
SSc and immunodominant topoisomerase I, 1179
tumor necrosis factor α microsatellite polymorphisms and RA outcome, 2698
Epoprostenol, SSc-associated pulmonary hypertension and, 2638
Epstein-Barr virus (EBV)
and lymph node changes in RA treated with MTX, 1773
RA risk, HLA-DR4, and, 1485
as risk factor for SLE in children and adolescents, 1782
Estrogen
enhancement of antibodies in SLE, 328
ovarian failure and SLE flares, 1274
replacement therapy modulation of insulin-like growth factor in monkey, 2103
synthase locus in RA, 1617
Ethnicity
differences in SSc, 465
genetic risk and protective factors for myositis, 1285
RA, HLA-DRB1 alleles, and, 1329
SLE and, 1560
Exercise
in hip or knee OA, 1361
serum markers in RA after, 1861

F

Fas/Fas ligand
apoptotic defects in SLE with CD95 mutations, 1833
–induced apoptosis and c-*myc* oligonucleotides in RA, 954
inflammatory myopathies and, 291
–mediated apoptosis in synoviocytes and tumor necrosis factor α, 519
Fcγ receptor IIIA, in lupus nephritis, 818
Fcγ receptor type IIa
polymorphisms in SLE, 1828
polymorphisms in Wegener's granulomatosis, 1823
Fibrillin 1, autoantibodies in localized SSc, 2656
Fibroblasts
collagenase 3 in RA, 1517
gene transfer of cytokine inhibitors into synovial, 490
IL-7 and IL-15 production by fibroblast-like synoviocytes in RA, 1508
nimesulide and glucocorticoid receptors in, 157
p53 gene in RA synovial, 1594
SSc and differential expression of mRNA in, 1451

Fibromyalgia
Chiari malformation in, 2731
function and disability in community, 76
physical and emotional trauma and, 828
psychological associations with, 1397
serotonin transporter gene in, 2482
Filtration leukocytapheresis, in RA, 431
Fingers, arthritis of, 1232
Fluorosis, osteomalacia and, 2012
Fluoxetine, inhibitory effects in synovial cells, 2561
Folate receptor β, in RA synovial macrophages, 1609
Fractures
collagen type I polymorphisms and risk of, 285
OA, alendronate, and risk of, 1246
OA, bone loss, and risk of, 1378
in SLE, 882
subchondral insufficiency, of femoral head, 2719
Freyberg, Richard H., obituary, 1321
Function, disability and, in fibromyalgia, 76

G

Genetics
apoptotic defects with CD95, 1833
autoimmune sialadenitis in MRL/lpr lupus-prone mice, 2616
in Behçet's disease, 1961
β_2-glycoprotein I polymorphism in antiphospholipid syndrome, 1655
chemokine receptor CCR5 in RA, 989
chromosome mapping of human cartilage intermediate layer protein in CPPD deposition syndromes, 2139
chromosome 1q41 linkage with SLE, 1902
CYP19 locus in RA, 1617
in familial antiphospholipid antibody syndrome, 318
FcγR polymorphisms, 1823, 1828
gene therapy for rheumatic diseases, 1
genome scan of multiple loci in proteoglycan-induced RA in mouse model, 2524
glutathione S-transferase M1 in SS, 2612
HLA class II in congenital complete heart block, 1757
HOXD9 in joint development and arthritis, 686
in idiopathic inflammatory myopathy, 1285
Ig gene transcripts in SS, 240
JRA as complex genetic trait, 2261
mannose-binding lectin polymorphisms and infections in SLE, 2145
MICA-A9 allele and susceptibility to psoriatic arthritis, 1010
MRI study of disc degeneration in twins and, 366
nuclear factor κB decoy transfer for collagen-induced arthritis in, 2532
in OA, 39, 397, 1729
p53 in RA, 948, 1088, 1594
in RA, 648, 948, 989, 1071, 1088, 1594, 1617, 2524, 2698
serotonin transporter gene in fibromyalgia, 2482
serum markers in familial OA, 39
SS and p53 mutations and, 1466
stable transfection of human fetal chondrocytes with collagen type II minigene, 1433
systematic vIL-10 gene delivery in mouse RA, 678
tumor necrosis factor α gene polymorphisms and HLA genes in JRA, 2577
tumor necrosis factor α microsatellite polymorphisms and RA outcome, 2698
Geographic tongue, 1061
Giant cells, cathepsin K mRNA in OA synovial, 1588
Giant cell (temporal) arteritis
acute-phase response and ischemic risk in, 190
arterial wall injury in, 844
blindness and cerebrovascular accidents in, 825
disease pattern in cranial and large-vessel, 311
Giant cell (temporal) arteritis *(cont'd)*
disease patterns, 2258
irreversible cranial ischemic complications and, 2256
musculoskeletal manifestations of, 1259
parvovirus B19 in pathogenesis of, 1255
skin necrosis in, 1296
temporal artery biopsy in diagnosis of systemic necrotizing vasculitis, 2674
YKL-40 and, 2624
Global statistical tests, multiple treatment outcomes in RA and, 1879
Glomerulonephritis, anti-C1q antibodies and Fcγ polymorphisms in SLE, 1828
Glucocorticoids
congenital complete heart block and fluorinated, 2335
fat conversion of marrow and treatment with, 1405
immunomodulatory role of, 393
receptor system and nimesulide, 157
in staged approach in treatment of Wegener's granulomatosis, 2666
Glucose metabolism, in SLE, regional cerebral blood flow and brain, 61
Glutathione S-transferase M1, in SS, 2612
Glycoprotein-39 human cartilage antigen, differential function of HLA-DRB4*0401 and HLA-DRB4*0402 in RA, 1497
Glycoproteins
differential function of HLA-DRB4*0401 and HLA-DRB4*0402 in RA, 1497
HLA class II alleles and anti-β_2, 268
plasma cell glycoprotein-1 and B10 in inorganic pyrophosphate metabolism in chondrocytes, 1986
protein C inhibition and monoclonal anticardiolipin antibodies, 167
Goat models, cartilage collagen destruction and oncostatin M in, 2543
Gout
osteochondromatosis and acute, 2011
polyarticular and tophaceous, 1784
Granulocyte colony-stimulating factor, hematopoietic stem cell mobilization in refractory RA, and cyclophosphamide administration, 2275
Granulocyte–macrophage colony-stimulating factor, synovial nurse-like cells in RA and, 221
Guinea pig models, matrix metalloproteinase expression in, 590

H

Hand
menopause, BMD, and incidence of OA, 483, 2497
radiographic progression, grip strength and OA, 33
Health Assessment Questionnaires (HAQs), 1854, 2213
health status questionnaires, 1797
multidimensional, 2220
in SSc, 2372
Health insurance, health care evaluations and, 2710
Hemarthrosis, 1025, 1033
Hematoma, spinal epidural, complicating active systemic lupus erythematosus, 577
Hemochromatosis, parathyroid hormone and, 799
Hemoglobin, effects on streptococcal cell wall–induced tissue injury, 1119
Hemophilia, 1025
femoral head osteonecrosis in childhood, 1550
Hepatitis B, SLE after vaccination against, 1307
Hepatitis C virus
extrahepatic manifestations of, 2204
IFNα anti-angiogenic activity in cryoglobulinemia with, 1051
SS and non-Hodgkin's lymphoma, 2489
in type II cryoglobulinemia, 1898
High-dose immunosuppressive therapy for RA, 2269
Hip
exercise therapy in OA of, 1361

Hip *(cont'd)*
genetics of OA of, 1729
replacement outcomes predictors in OA, 1722
Histones, termination of histone-specific T cell anergy, 2449
HLA-B27
disease chronicity and tumor necrosis factor α in reactive arthritis, 2039
early synovitis associated with, 1696
peptide specificity of B*2705, B*2704, and B*2706 in AS, 1975
peptide supermotif for spondylarthropathy and, 175
HLA-B39, peptide supermotif for spondylarthropathy and, 175
HLA-B51, association with Behçet's disease, 1961
HLA class I
age-specific effects of JRA-associated, 1843
complete congenital heart block and maternal, 1757
tumor necrosis factor α gene polymorphisms and HLA genes in JRA, 2577
HLA class II
age-specific effects of JRA-associated, 1843
anti-β_2 glycoproteins and, 268
complete congenital heart block and maternal, 1757
tumor necrosis factor α gene polymorphisms and HLA genes in JRA, 2577
HLA-DQ, in RA, 1621
HLA-DR, T cell receptor usage among Sm-B–specific T cell, 703
HLA-DR1, in polymyalgia rheumatica, 1561
HLA-DR4
clues to arthritogenic peptide motifs in RA and, 1040
differential function of HLA-DRB4*0401 and HLA-DRB4*0402 in RA, 1497
RA risk, EBV, and, 1485
type II collagen antibodies in RA and, 2569
HLA-DR7, type II collagen antibodies in RA and, 2569
HLA-DRB1
alleles in Mexican Americans with RA, 1329
alleles and rheumatoid factor influence on outcome of RA, 2174
ethnic differences in SSc and, 465
in giant cell (temporal) arteritis, 311
in idiopathic inflammatory myopathy, 1285
in inflammatory polyarthritis, 757
QR/KRAA and RA, 2015
in RA, 1621
RA severity and tumor necrosis factor α microsatellite polymorphism and, 438
tumor necrosis factor α microsatellite polymorphisms and RA outcome, 2698
type II collagen antibodies in RA and, 2569
HLA-DRB1*0404
IFN-β-1a-induced arthritis with, 569
in inflammatory polyarthritis, 757
HLA phenotype, congenital complete heart block and maternal, 1757
Hodgkin's disease, lymph node changes in RA treated with MTX, 1773
HOXD9, in joint development and arthritis, 686
Human cytomegalovirus. *See* Cytomegalovirus
Human immunodeficiency virus (HIV), diffuse infiltrative lymphocytosis syndrome with anti–52-kd Ro/SSA and type 1, 578
Human retrovirus 5, in arthritis and SLE, 448, 2492
Hyaluronan
in canine OA, 1159
CD44 and joint inflammation, 659
CPPD arthritis and, 1302
pyrophosphate arthritis after intraarticular injection of, 594
serum levels in RA, 1861
Hyaluronic acid, fluoxetine and amitriptyline inhibitory effects on, 2561
Hydroxychloroquine, dose-loading in RA, 357, 1556
Hyper-IgM syndrome, X-linked, 1291
Hyperostosis sternoclavicularis, sacroiliitis, psoriasis palmoplantaris, and, in twins, 574
Hyperparathyroidism, versus lymphoma, 1559
Hypertrophic osteoarthropathy, in Whipple's disease, 2002
as first indication of lung carcinoma, 2736
in Whipple's disease, 2002

I

Idiopathic inflammatory myopathy
Childhood Myositis Assessment Scale, 2213
genetic risk and protective factors for, 1285
IgG
anticardiolipin autoantibodies in antiphospholipid syndrome, 2461
anti–endothelial cell antibodies, 631
anti–lamin B1 in SLE, 1347
antiprothrombin antibodies and coagulation in primary antiphospholipid syndrome, 2132
estrogen enhancement of antibodies in SLE and, 328
oligosaccharides in rheumatic diseases, 1682
Iloprost, in SSc, 196
Imaging. *See also* Magnetic resonance imaging (MRI)
neuroimaging in neuropsychiatric SLE, 2026
Immunizations, in SLE, 1307
Immunologic homunculus, in RA, 2499
Infection
bacterial components in *Salmonella*-triggered reactive arthritis, 84
complement deficiency and risk in SLE, 2023
mannose-binding lectin polymorphisms in SLE and, 2145
Inflammatory arthritis, hemoglobin effects on streptococcal cell wall–induced tissue injury, 1119
Inflammatory myopathies, Fas/Fas ligand and apoptosis in, 291
Infliximab, and MTX in RA, 1779
Injections, pyrophosphate arthritis after intraarticular hyaluronan, 594
Insulin-like growth factor
estrogen replacement therapy modulation of, in monkey models, 2103
urokinase plasminogen activity regulation by, in human osteoblasts, 2112
Interferon-α (IFNα)
anti-angiogenic activity in cryoglobulinemia, 1051
therapy in scleroderma, 299
Interferon-β (IFNβ), gene therapy in murine collagen-induced arthritis, 90
Interferon-β-1a (IFN-β-1a), -induced arthritis with HLA-DRB1*0404 allele, 569
Interferon-γ (IFNγ)
cytokine profiles in Wegener's granulomatosis and, 742
IFNβ gene therapy in murine collagen-induced arthritis and, 90
macrophage migration inhibitory factor in RA and, 1601
in SSc lung disease, 1168
Interleukin-1 (IL-1)
anti–endothelial cell antibodies and, 631
chondrocytes in OA and, 1147
–converting enzyme in OA, 1577
in leukemic arthritis, 831
macrophage migration inhibitory factor in RA and, 1601
nitric oxide inhibition of transforming growth factor β production by chondrocytes, 248
nitric oxide synthase inhibitor mediation of cartilage effect, 2094
opsonized dendritic cells and, 1412
polymorphisms in RA, 1093
retinoic acid–induced degradation of type II collagen and, 137
synovial nurse-like cells in RA and, 221
Interleukin-1 receptor antagonist (IL-1Ra)
polymorphisms in RA, 1093
sustained blood levels in rat models of arthritis, 498

Interleukin-2 (IL-2)
in giant cell (temporal) arteritis, 311
transforming growth factor β and dendritic cells in RA and, 507
Interleukin-4 (IL-4)
cytokine inhibition of tumor necrosis factor α–induced prostaglandin E_2 and, 710
cytokine profiles in Wegener's granulomatosis and, 742
–deficient mice, collagen-induced arthritis in, 1635
polymorphisms in RA, 1093
in SLE, 1298
in SSc lung disease, 1168
Interleukin-6 (IL-6)
α_1-antitrypsin induction by, 1936
–deficient mice, collagen-induced arthritis in, 1635
in neuropsychiatric SLE, 2730
synovial nurse-like cells in RA and, 221
taurine chloramine inhibitory function in RA and, 2552
Interleukin-7 (IL-7), production by RA fibroblast-like synoviocytes, 1508
Interleukin-8 (IL-8)
chemotaxis in endothelial cells in RA and, 1927
synovial nurse-like cells in RA and, 221
taurine chloramine inhibitory function in RA and, 2552
Interleukin-10 (IL-10)
cytokine inhibition of tumor necrosis factor α–induced prostaglandin E_2 and, 710
–deficient mice, collagen-induced arthritis in, 1635
estrogen enhancement of antibodies in SLE and, 328
gene expression and JRA phenotype, 1101
IL-12 regulation of murine collagen-induced arthritis and, 100
opsonized dendritic cells and, 1412
polymorphisms in RA, 1093
promoter polymorphism and lupus nephritis, 590
in RA, 2017
in SLE multicase families, 1649
systematic vIL-10 gene delivery in mouse RA, 678
Interleukin-12 (IL-12)
IFNβ gene therapy in murine collagen-induced arthritis and, 90
RA synovial cell production of, 1917
regulation of murine collagen-induced arthritis, 100
Th1 and immune response in Behçet's disease, 1967
Interleukin-13 (IL-13), cytokine inhibition of tumor necrosis factor α–induced prostaglandin E_2 and, 710
Interleukin-15 (IL-15), production by RA fibroblast-like synoviocytes, 1508
Interleukin-17 (IL-17)
chondrocyte nitric oxide production regulation by, 2399
in RA synovial tissue, 963
Intestinal pseudoobstruction, octreotide in connective tissue disease, 1545
Ischemia
acute-phase response in giant cell (temporal) arteritis and, 190
in giant cell (temporal) arteritis, 2256
IFNα anti-angiogenic activity with hepatitis C virus and cryoglobulinemia, 1051

J

Joint lavage, steroid injection and, in knee OA, 475
J proteins, human DnaJ homologs in RA, 210
Juvenile chronic arthritis, bone densitometry in adults with history of, 790
Juvenile idiopathic inflammatory myopathy, Childhood Myositis Assessment Scale, 2213
Juvenile-onset systemic lupus erythematosus, antiribosomal P antibodies in, 69
Juvenile rheumatoid arthritis (JRA)
age-specific effects of HLA alleles in, 1843
Juvenile rheumatoid arthritis (JRA) *(cont'd)*
as complex genetic trait, 2261
IL-10 gene expression and, 1101
Intraarticular steroids, in prevention of leg length discrepancy in pauciarticular, 2330
lipoprotein abnormalities in active, 373
naproxen-induced pseudoporphyria in, 2252
tumor necrosis factor α gene polymorphisms and HLA genes in, 2577

K

Keratin sulfate
in canine OA, 1159
immune response to link protein and G1 domain in OA, 527
serum markers in familial OA, 39
Knee
aggrecan turnover in injury of, 534
estrogen replacement therapy modulation of insulin-like growth factor in monkey, 2103
exercise therapy in OA of, 1361
genetics of OA of, 1729
high-resolution 3-D MRI in antigen-induced arthritis in rabbits, 119
joint lavage and steroid injection in, 475
laxity, strength, and function in, 25
menopause, BMD, and incidence of OA in, 483, 2497
OA risk factors in middle-aged women, 17
replacement outcomes predictors in OA, 1722
self-care education benefits in OA of, 1267

L

Lamin B1, SLE and lupus anticoagulant and anti–, 1347
Laxity, in knee OA, 25, 861, 2734, 2735
Lectin, mannose-binding polymorphisms and infections in SLE, 2145
Leflunomide, combination therapy with MTX and, in RA, 1322, 1870
Leishmania infantum, in etiology of cryoglobulinemia, 2007
Leishmaniasis, cryoglobulinemia in visceral, 2007
Leukemic arthritis, interleukin-1β secretion in, 831
Leukocytapheresis
filtration, in RA, 431
RA and, 2255
Lipoproteins
abnormalities in JRA, 373
autoantibodies against malondialdehyde-modified lipoprotein(a) in antiphospholipid syndrome, 2606
RA and apolipoproteins and serum, 443
RA and atherosclerosis and, 2491
Losartan, for Raynaud's phenomenon and SSc, 2646
Luciferase, dominant-negative p53 mutations in RA and, 1088
Lupus, neonatal, congenital complete heart block and fluorinated glucocorticoids in, 2335
Lupus nephritis
antiribosomal P antibodies in, 2729
Fcγ receptor IIIA alleles in, 818
IL-10 promoter polymorphism and, 590
Th1 cells in, 1644
Lyme disease, *Borrelia burgdorferi* in arthritis in, 1473, 1809, 1813, 2705
Lymphoma
versus hyperparathyroidism, 1559
primary SS and malignant, 1765
in RA treated with MTX, 1773
SS and p53 mutations and, 1466
Lymphomagenesis, Ig gene transcripts in SS and, 240

M

Macrophage migration inhibitory factor, in RA, 1601
Macrophages
  synovial nurse-like cells in RA and granulocyte–macrophage colony-stimulating factor, 221
  in synovial tissue in RA, folate receptor β and, 1609
Magnetic resonance imaging (MRI)
  in antigen-induced arthritis in rabbits, 119
  in assessment of arthritis in finger joints, 1232
  in assessment and prognostication of RA, 918
  fat conversion of marrow and treatment with glucocorticoids, 1405
  in rat adjuvant-induced arthritis, 2060
  regional cerebral blood flow and brain glucose metabolism in SLE and, 61
  sonography and, assessment of rotator cuff tears, 2231
  study of disc degeneration in twins and, 366
  in synovitis and bone changes in early untreated RA, 1706
  Takayasu arteritis and gadolinium-enhanced, 1549
Major histocompatibility complexes (MHC), T cell receptors in spontaneous murine arthritis, 2517
Major histocompatibility complex (MHC) class I
  antiproteasomal antibodies in primary SS, 697
  HLA-B51 and, in Behçet's disease, 1961
Major histocompatibility complex (MHC) I-A^{g7}, T cell receptor and T cell receptor ligand in murine spontaneous arthritis and, 2517
Malondialdehyde-modified lipoprotein(a), autoantibodies against, in antiphospholipid syndrome, 2606
Managed care, health care evaluations and health insurance, 2710
Mannose-binding lectin, polymorphisms and infections in SLE, 2145
Markov cost-effectiveness model, in RA, 347
Matrix metalloproteinases. *See* Metalloproteinases
Menopause
  BMD and OA incidence in, 483, 2497
  ovarian failure and SLE flares, 1274
Messenger RNA (mRNA), differential expression of in SSc, 1451
Metalloproteinases
  collagenase 3 in RA, 1517
  collagenase regulation in OA and, 719
  collagen damage initiation and, 2074
  epitopes in mouse arthritis, 1128
  expression in guinea pigs, 590
  inhibition by doxycycline, 1140
  inhibitors and cartilage breakdown in OA, 129
  metargidin mRNA up-regulation in OA and normal cartilage, 1946
  retinoic acid–induced degradation of type II collagen and, 137
  serum levels in RA, 1861
  systematic vIL-10 gene delivery in mouse RA and, 678
Metargidin, mRNA up-regulation in OA and normal cartilage, 1946
Methotrexate (MTX)
  folate receptor β in RA synovial macrophages and, 1609
  leflunomide combination therapy in RA and, 1322, 1870
  lymph node changes in RA treated with, 1773
  in RA, every-other-week therapy for maintaining remission, 2160
  RA and infliximab and, 1779
  in staged approach in treatment of Wegener's granulomatosis, 2666
Mi-2 antigen, dermatomyositis and, 1552
MICA-A9 allele, susceptibility to psoriatic arthritis and, 1010
MIC-A alleles, association with Behçet's disease, 1961
Minocycline, in early RA, 1691
Misoprostol, diclofenac cost effectiveness in RA and, 2293
Mitogen-activated protein kinase, in chondrocyte nitric oxide production regulation by IL-17, 2399
Mixed connective tissue disease (MCTD)
  as distinct disease entity, 190, 191, 193
  outcomes in, 899
Monkey models, estrogen replacement therapy modulation of insulin-like growth factor in, 2103
Monoclonal antibodies
  protein C activity and, 167
  sequence features of, 1783
Monocyte chemoattractant protein-1, chemotaxis in endothelial cells in RA and, 1927
Morbidity
  musculoskeletal disorders, prevalence in US, and, 769
  in SLE, 338
Mortality
  hospital experience and mortality in SLE, 891
  incidence and mortality trends of SLE, 46, 2021
Mouse models
  aggrecanase and metalloproteinase neoepitopes in, 1128
  CD44 and joint inflammation, 659
  collagen, type II degradation during OA, 2381
  collagen-induced arthritis in IL-6–deficient, 1635
  cytokines in collagen-induced arthritis in, 1109
  differential function of HLA-DRB4*0401 and HLA-DRB4*0402 in RA, 1497
  genetic basis of autoimmune sialadenitis in MRL/lpr lupus-prone mice, 2616
  gene transfer of cytokine inhibitors into synovial fibroblasts, 490
  genome scan of multiple loci in proteoglycan-induced RA in, 2524
  HOXD9 in joint development and arthritis, 686
  IFNβ gene therapy in collagen-induced arthritis, 90
  of IL-12 regulation of collagen-induced arthritis, 100
  induced anti-Ro in, 1017
  lack of endothelial cell apoptosis in SSc, 581
  modulation of oral tolerance to type II collagen by cytokines in, 110
  nuclear factor κB decoy transfer for collagen-induced arthritis in, 2532
  systematic vIL-10 gene delivery in RA, 678
  T cell receptor and T cell receptor ligand in spontaneous arthritis, 2517
  type II collagen–cholera toxoid conjugate vaccine in collagen-induced arthritis in, 1628
  vasculitis in Palmerston North, 561
  Yersinia enterocolitica–associated arthritis in tumor necrosis factor receptor p55, 1662
Multidimensional Health Assessment Questionnaire, 2213
Musculoskeletal manifestations
  of giant cell (temporal) arteritis, 1259
  prevalence in US, 769
Mutations. *See also* Polymorphisms
  apoptotic defects with CD95, 1833
  dominant-negative p53 in RA, 1088
Mycobacterium tuberculosis, cerebral vasculitis associated with, 383
Myositis, genetic risk and protective factors for, 1285

N

Naproxen
  glucocorticoid receptors and, 157
  -induced pseudoporphyria in JRA, 2252
  OA pain treated with tramadol and, 1370
Necrosis, giant cell (temporal) arteritis and skin, 1296
Necrotizing vasculitis
  nonsystemic, of peripheral nervous system, 824
  Vasculitis Activity Index validation for, 2365
Neoepitopes
  aggrecanase and metalloproteinase, 1128
  stromelysin and initiation of collagen damage, 2074
Neonatal lupus, congenital complete heart block and fluorinated glucocorticoids in, 2335
Neoplasms, associated with Wegener's granulomatosis, 751
Nephritis, anti-C1q autoantibodies and SLE, 187
Neuropsychiatric systemic lupus erythematosus. *See* Systemic lupus erythematosus (SLE)

Neutropenia, cyclophosphamide-induced, in Wegener's granulomatosis, recombinant human granulocyte colony-stimulating factor in treatment of, 1752
Nimesulide, glucocorticoid receptors and, 157
Nitric oxide
fluoxetine and amitriptyline inhibitory effects on, 2561
hemoglobin effects on streptococcal cell wall–induced tissue injury and, 1119
IFN-β-1a–induced arthritis with HLA-DRB1*0404 allele and, 569
inhibition of transforming growth factor β production by chondrocytes, 248
production and apoptosis, in the meniscus in OA in rabbit models, 2123
production regulation by IL-17 in osteoarthritic chondrocytes, 2399
synthase inhibitor protection of cartilage, 2094
synthase stimulation in articular cartilage by *Staphylococcus aureus*, 2410
Nomenclature, for neuropsychiatric systemic lupus erythematosus, 599
Non-Hodgkin's lymphoma, hepatitis C virus, SS and, 2489
Nonsteroidal antiinflammatory drugs (NSAIDs)
glucocorticoid receptors and nimesulide, 157
misoprostol and diclofenac cost effectiveness in RA and, 2293
Nuclear factor κB
in chondrocyte nitric oxide production regulation by IL-17, 2399
decoy transfer for collagen-induced arthritis, 2532
in Takayasu arteritis, 1421
Nucleoside triphosphate pyrophosphohydrolase, plasma cell glycoprotein-1 and B10 in inorganic pyrophosphate metabolism in chondrocytes, 1986
Nucleosomes, in SLE, 833, 2733, 2734
Nurse cells, synovial nurse-like cells in RA, 221

O

Obituaries
Freyberg, Richard H., 1321
Stillman, James Sydney, 1087
Octreotide, in intestinal pseudoobstruction in connective tissue disease, 1545
Oligoarthritis
ciprofloxacin in, 1386
geographic tongue and, 1061
Oligonucleotides. *See also* Nuclear factor κB
c-*myc*, in RA, 954
nuclear factor κB decoy transfer for collagen-induced arthritis in, 2532
Oncostatin M, cartilage collagen destruction in goat joints and, 2543
Opioids, for pain in rheumatic diseases, 830
Opsonization, apoptotic cells as antigen source for dendritic cells and, 1412
Osteoarthritis (OA)
in adults with history of juvenile chronic arthritis, 790
aggrecan turnover in knee injury in, 534
alendronate, bone density changes, and fracture risk in, 1246
apoptosis and nitric oxide production in the meniscus in rabbit models, 2123
BMD, menopause, and incidence of, 483, 2497
bone loss and fracture risk in, 1378
calcitonin in canine, 1159
cathepsin K mRNA in synovial giant cells in, 1588
collagen type II degradation during murine, 2381
collagen type II degradation following anterior cruciate ligament rupture, 2390
collagenase 3 production by chondrocytes in human, 1147
collagenase regulation in, 719
diacerhein in canine, 545
exercise in hip or knee, 1361
genetics and, 397, 1729
Osteoarthritis (OA) *(cont'd)*
grip strength and radiographic hand, 33
hip/knee replacement outcome predictors, 1722
IL-1β–converting enzyme in, 1577
immune response to link protein and G1 domain in, 527
joint lavage and steroid injection in knee, 475
laxity in knee, 25, 861, 2734, 2735
metalloproteinase inhibitors and cartilage breakdown in, 129
naproxen and tramadol and pain of, 1370
progressive imbalance in OA of aggrecan and type II collagen, 993
radiographic knee, risk factors in middle-aged women, 17
segregation analysis of radiographic progression in, 1068
self-care education benefits in knee, 1267
serum cartilage oligomeric matrix protein levels and, 2356
serum vitamin D in hip, 854
transforming growth factor β, avocado/soybean unsaponifiables and articular chondrocyte expression in, 148
type II procollagen in OA, 1443
urokinase plasminogen activity regulation by insulin-like growth factor-1 in human osteoblasts, 2112
Osteoblasts, urokinase plasminogen activity regulation by insulin-like growth factor-1 in human, 2112
Osteochondromatosis, acute gout and, 2011
Osteomalacia, fluorosis and, 2012
Osteonecrosis
childhood hemophilia and femoral head, 1550
fat conversion of marrow and treatment with steroids, 1405
Osteoporosis
cystic fibrosis and, 1563
prevention of corticosteroid-induced, 1736
type I collagen polymorphisms and, 285
vitamin D and corticosteroid-induced, 1740
Outcomes
functional capacity determinants in RA, 1854
HLA-DRB1 and RF influence on RA, 2174
in MCTD, 899
multiple treatment comparisons in RA, 1879
OA hip/knee replacement predictors, 1722
SSc and pregnancy and fertility, 763
tumor necrosis factor α microsatellite polymorphisms and RA, 2698
Ovaries
failure and flares of SLE, 1274
failure and thalidomide treatment, 2259

P

p205, T cell proliferation in RA and, 971
Pain
OA pain and naproxen and tramadol, 1370
opioids in rheumatic disease, 830
Pannus, and high-resolution ultrasound of metacarpophalangeal and proximal interphalangeal joints in RA, 2303
Papillomavirus, in primary SS, 1064
Parathyroid hormone, hemochromatosis and, 799
Parvovirus, B19 in pathogenesis of giant cell (temporal) arteritis, 1255
Pediatric rheumatologists, 396
Peptides
clues to arthritogenic peptide motifs in RA, 1040
induced anti-Ro in mice, 1017
neuropeptides modulate RA synovial cell function, 2418
specificity of B*2705, B*2704, and B*2706 in AS, 1975
supermotif for spondylarthropathy and, 175
^{99m}Tc-labeled E-selectin–binding peptide in rat adjuvant arthritis, 641
Pericytes, activation in Raynaud's phenomenon and SSc, 930
p53 gene
in RA, 948, 1088, 1594
SS and lymphoma and, 1466

P-glycoproteins, drug resistance in RA and, 2014
Phorbol myristate acetate, collagenase regulation in OA by, 719
Pigmented villonodular synovitis, telomerase activity in RA and, 669
Pig models, signaling pathways of chondrocyte inorganic pyrophosphate, 555
Pityriasis rubra pilaris, anti–tumor necrosis factor α immunotherapy in inflammatory arthritis and, 1998
Plasminogen activator inhibitor, avocado/soybean unsaponifiables in OA and, 148
Platelet-activating factor acetylhydrolase, in JRA, 373
Platelet-derived growth factor, pericyte activation in Raynaud's phenomenon and SSc and, 930
Pneumocystis carinii, pneumonia in connective tissue disease, 780
Pneumonia, in connective tissue disease and *Pneumocystis carinii*, 780
Poly(ADP-ribose) polymerase, alleles and susceptibility to SLE or antiphospholipid syndrome, 2194
Polyangiitis, microscopic, 421
Polyarteritis nodosa, antiphospholipid antibodies with Wegener's granulomatosis and, 2250
Polyarthritis
  HLA-DRB1 alleles in inflammatory, 757
  IFN-β-1a–induced arthritis with HLA-DRB1*0404 allele, 569
Polyarticular arthritis, hyper-IgM syndrome and, 1291
Polymorphisms
  β_2-glycoprotein I, 1189
  collagen type II COL2A1 and familial OA, 39
  FcγR, in SLE, 1828
  FcγR, in Wegener's granulomatosis, 1823
  interleukin, in RA, 1093
  lupus nephritis and IL-10 promoter, 590
  mannose-binding lectin, and infections in SLE, 2145
  MICA-A9 allele and susceptibility to psoriatic arthritis, 1010
  osteoporosis and type I collagen, 285
  RA and cytokine gene, 1093
  RA severity and tumor necrosis factor α microsatellite, 438
  serotonin transporter gene in fibromyalgia, 2482
  in SLE, 1298
  T cell receptor ζ chain, in SLE, 2601
  tumor necrosis factor α and RA outcome, 2698
  tumor necrosis factor α gene and HLA genes in JRA, 2577
Polymyalgia rheumatica
  in disease pattern in cranial and large-vessel giant cell (temporal) arteritis, 311
  erythrocyte sedimentation rate and diagnosis of, 827
  musculoskeletal manifestations in, 1259
  synovitis and HLA-DR1 in, 1561
Polymyositis (PM), inflammatory myopathies and Fas/Fas ligand–induced apoptosis, 291
Polyomavirus T antigen
  DNA and antibodies to, 2583
  termination of histone-specific T cell anergy, 2449
Prednisolone, fat conversion in marrow in treatment with, 1405
Prednisone
  carotid plaque in SLE and, 51
  corticosteroid-induced osteoporosis and, 1736
Pregnancy
  RA and, 1219
  SSc and outcome of fertility and, 763
Primary care, in rheumatology practice, 409
Procainamide, -induced SLE, 1300
Prosorba column, treatments for refractory RA, 2153
Prostacyclin, SSc-associated pulmonary hypertension and, 2638
Prostaglandin E_2
  cytokine inhibition of tumor necrosis factor α–induced, 710
  fluoxetine and amitriptyline inhibitory effects on, 2561
  purine receptor expression in articular chondrocytes, 258
Proteasome inhibitor, apoptosis induction by, 2440
Protein
  chromosome mapping of human cartilage intermediate layer protein in CPPD deposition syndromes, 2139
  immune response to link protein and G1 domain in OA, 527
  role of carrier protein in immunosorbent assay for antiribosomal P antibodies, 593
  serum cartilage oligomeric matrix protein levels in OA, 2356
  T cell reactivity to outer surface protein A in Lyme arthritis, 1813
Proteinase 3, Wegener's granulomatosis and, 384, 751, 2494
Protein kinase A-I, in SLE, 1458
Proteoglycans
  immune response to link protein and G1 domain in OA, 527
  -induced RA, CD44 and joint inflammation, 659
  -induced RA, genome scan of multiple loci in murine model of, 2524
  inducible nitric oxide synthase stimulation in articular cartilage by *Staphylococcus aureus*, 2410
  matrix metalloproteinase inhibitors and cartilage breakdown in OA, 129
  nitric oxide inhibition of transforming growth factor β production by chondrocytes, 248
  synthesis of chondrocytes, nonenzymatic glycation and, 1003
Pseudogout, aggrecan turnover in, 534
Pseudoporphyria, naproxen-induced, in JRA, 2252
Psoriasis palmoplantaris, sacroiliitis, hyperostosis sternoclavicularis, and, in twins, 574
Psoriatic arthritis
  early treatment and prognosis in, 189
  excessive paternal transmission in, 1228
  geographic tongue and, 1061
  immunogenetic profile of, 822
  MICA-A9 allele and susceptibility to, 1010
  Streptococci molecular marker in, 2055
  unified concept of, 1080
  vascular patterns of early synovitis in, 1481
Psychology, fibromyalgia associated with, 1397
Pulmonary disease
  prostacyclin in SSc-associated pulmonary hypertension, 2638
  in SS, 2249
  SSc-associated pulmonary hypertension and prostacyclin, 2638
  type 2 cytokines in lung disease in SSc, 1168
  type 2 cytokines in SSc, 1168
Purine receptors, expression in articular chondrocytes, 258
Pyridinyl bisphosphonate, risedronate in prevention of steroid-induced bone loss, 2309
Pyrophosphate, inorganic
  chondrocyte signaling pathways, 555
  plasma cell glycoprotein-1 and B10 in chondrocyte metabolism of, 1986
Pyrophosphate arthritis, after intraarticular injection of hyaluronan, 594

Q

Questionnaires, health status. *See* Health Assessment Questionnaires (HAQs)

R

Rabbit models
  apoptosis and nitric oxide production in the meniscus in OA in, 2123
  high-resolution 3-D MRI in antigen-induced arthritis in, 119
Radiographic progression
  DMARDs and RA, 1066
  grip strength and hand OA, 33
  in RA, 2498
  risk factors in middle-aged women, 17
  segregation analysis and OA, 1068
  vitamin D and hip OA, 854

Rat models
annexin I inhibition in adjuvant arthritis in, 1538
MRI in rat adjuvant-induced arthritis, 2060
neurogenically induced damage in cartilage, 1951
nitric oxide synthase inhibitor protection of cartilage in, 2094
sustained IL-1Ra blood levels in arthritis, 498
^{99m}Tc-labeled E-selectin–binding peptide in adjuvant arthritis, 641
Raynaud's phenomenon
losartan for, 2646
pericyte activation in SSc and, 930
sex differences in, 306
Reactive arthritis
Chlamydia trachomatis antibodies in, 942
ciprofloxacin in, 1386
ciprofloxacin in anterior uveitis and, 1894
Salmonella-triggered, bacterial components in, 84
Salmonella-triggered, modulation of peripheral blood mononuclear cell activation in, 2045
tumor necrosis factor α and disease chronicity in, 2039
vascular patterns of early synovitis in, 1481
Yersinia pseudotuberculosis in, 2239
Recombinant human granulocyte colony-stimulating factor, in Wegener's granulomatosis, 1752
Renal cell carcinoma, in Wegener's granulomatosis, 751
Reproducibility, assessment methodology for, 1556, 1557
Retinoic acid–induced degradation of type II collagen and IL-1α, 137
Retrovirus, gene transfer of cytokine inhibitors into synovial fibroblasts, 490
Reverse transcription polymerase chain reaction, differential expression of mRNA in SSc and, 1451
Rheumatic disease
health care evaluations and health insurance, 2710
IgG oligosaccharides in, 1682
reporting guidelines for, 585
Rheumatoid arthritis (RA)
adhesion molecules in, 1067
adrenomedullin in, 1297
apolipoprotein(a) and serum lipoprotein(a) phenotypes in, 443
arthritogenic peptide motif clues in, 1040
autologous hematopoietic stem cell transplantation in refractory RA, 2281
azathioprine loading in, 186
CCR5 chemokine receptor in, 989
CD97 and CD55 expression in, 650
CD146 in synovial fluid in, 622
chemotaxis inhibition by sulfasalazine in endothelial cells in, 1927
chondrocyte apoptosis in, 1528
clues to arthritogenic peptide motifs in, 1040
c-*myc* oligonucleotides in, 954
collagenase 3 in, 1517
collagen type II treatment of, 585
cost-effectiveness studies in, 347, 1209
cyclophosphamide and autologous blood stem cell rescue in severe, 2286
cytokines in collagen-induced arthritis in mice, 1109
cytotoxicity in, 954
Δ32CCR5 and, 2732
differential function of HLA-DRB4*0401 and HLA-DRB4*0402 in mice, 1497
disablement process in, 1712
DMARDs and drug resistance in, 2014
DMARDs in early, 1691
dominant-negative p53 mutations in, 1088
EBV, HLA-DR4, and risk of, 1485
epidemiology of, 415
estrogen synthase locus in, 1617
Rheumatoid arthritis (RA) *(cont'd)*
Fas/Fas ligand–mediated apoptosis in synoviocytes and tumor necrosis factor α, 519
fat conversion in marrow in treatment with steroids in, 1405
filtration leukocytapheresis in, 431
folate receptor β in synovial macrophages in, 1609
functional capacity determinants in, 1854
genetic revolution and, 1071
gene transfer of cytokine inhibitors into synovial fibroblasts in, 490
genome scan of multiple loci in murine model of proteoglycan-induced, 2524
hematopoietic stem cell mobilization in refractory, granulocyte colony-stimulating factor and cyclophosphamide administration, 2275
high-dose immunosuppressive therapy for, 2269
high-resolution ultrasound of metacarpophalangeal and proximal interphalangeal joints in, 2303
HLA-DQ in, 1621
HLA-DRB1 alleles in Mexican Americans with, 1329
HLA-DRB1 QR/KRAA and, 2015
HLA-DRB1 alleles and RF on outcome of, 2174
Hodgkin's disease and B cell lymphoproliferation in, 1773
HOXD9 in joint development and, 686
human DnaJ homologs in, 210
hydroxychloroquine dose-loading in, 357, 1556
IL-7 and IL-15 production by fibroblast-like synoviocytes in, 1508
IL-17 in synovial tissue in, 963
immunologic homunculus in, 2499
immunomodulatory role of glucocorticoids in, 393
incidence estimation of, 1339
interleukin polymorphisms in, 1093
leukocytapheresis and, 2255
lipoproteins and atherosclerosis in, 2491
macrophage migration inhibitory factor in, 1601
minocycline in early, 1691
misoprostol and diclofenac cost effectiveness in, 2293
monoclonal anti–tumor necrosis factor α and Th1 CD4+ T cells in, 2166
MRI in assessment and prognostication of, 918
MTX-associated lymph node changes in, 1773
MTX every-other-week therapy for maintaining remission, 2160
MTX and infliximab in, 1779
MTX and leflunomide combination therapy in, 1322, 1870
multiple outcomes treatment comparisons in, 1879
neuropeptide modulation of synovial cell function in, 2418
oral bovine type II collagen in treatment of, 1204
peripheral nerve involvement in, 1304
p53 gene in synovial fibroblasts in, 1594
p53 overexpression in, 948
pregnancy and, 1219
Prosorba column treatments for refractory, 2153
p205 and T cell proliferation in, 971
radiographic progression in, 2498
severity and tumor necrosis factor α microsatellite polymorphism, 438
sex role in severity of, 587, 588
smoking and risk of, 910
synovial nurse-like cells in, 221
synovitis and bone changes in early untreated, 1706
systematic vIL-10 gene delivery in mouse, 678
taurine chloramine inhibitory function in synoviocytes in, 2552
T cell response to type II collagen in, 2085
^{99m}Tc-labeled E-selectin–binding peptide in rat adjuvant arthritis, 641
telomerase activity in, 669
thioredoxin expression in, 2430
transforming growth factor β and dendritic cells in, 507

Rheumatoid arthritis (RA) *(cont'd)*
tumor necrosis factor α microsatellite polymorphisms and outcome in, 2698
vascular patterns of early synovitis in, 1481
Rheumatoid factor (RF)
HLA-DRB1 alleles and, influence on outcome of RA, 2174
p205 and T cell proliferation in RA, 971
Rheumatologists
pediatric, 396
primary care provision by, 409
training of, ACR and, 595
Risedronate, in prevention of steroid-induced bone loss, 2309
RNA polymerases, SSc and antibodies to, 275
Ro/SSA and La/SSB ribonucleoproteins
diffuse infiltrative lymphocytosis syndrome with anti–52-kd Ro/SSA and type 1 HIV, 578
fine specificity of antibody binding to, 199
Rotator cuff tears, sonography and magnetic resonance imaging assessment of, 2231
RP105, -negative B cells in SLE, 2593

S

Sacroiliitis, hyperostosis sternoclavicularis, psoriasis palmoplantaris, and, in twins, 574
Salivary glands, B7 expression by salivary gland epithelial cells in SS, 229
Salmonella, -triggered reactive arthritis, 84, 1386, 2045
SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis), response to doxycycline, 819
Sarcoidosis, osseous destruction in, 1065
Scleroderma. *See* Systemic sclerosis (SSc)
Selectins, ^{99m}Tc-labeled E-selectin–binding peptide in rat adjuvant arthritis, 641
Self-care, education benefits in knee OA, 1267
Septic arthritis, detection of bacterial DNA in, 2198
Serotonin transporter gene, in fibromyalgia, 2482
Sex
differences in Raynaud's phenomenon, 306
links in transmission of psoriatic arthritis, 1228
RA severity and, 587, 588
Sialadenitis, genetic basis of autoimmune, in MRL/lpr lupus-prone mice, 2616
Sjögren's syndrome (SS)
antiproteasomal antibodies in, 697
anti–Ro 52-kd monoclonal antibodies in, 2471
apoptosis of CD4+ T cells and disease activity in, 1673
B7 expression by salivary gland epithelial cells in, 229
genetic basis of autoimmune sialadenitis in MRL/lpr lupus-prone mice, 2616
glutathione S-transferase M1 in, 2612
hepatitis C virus, non-Hodgkin's lymphoma and, 2489
Ig gene transcripts in, 240
malignant lymphoma in, 1765
papillomavirus in, 1064
p53 mutations and lymphoma in, 1466
shrinking lung in, 2249
Sleep disturbances, in SLE, 2189
Smoking, risk of RA and, 910
Sonography, MRI and, assessment of rotator cuff tears, 2231
Spine
genetics of OA of, 1729
spinal epidural hematoma, complicating active systemic lupus erythematosus, 577
Spondylarthropathies
peptide supermotif for, 175
sulfasalazine in peripheral arthritis in seronegative, 2325
vascular patterns of early synovitis in, 1481
Staphylococcus aureus, inducible nitric oxide synthase stimulation in articular cartilage by, 2410
Statistics, multiple treatment outcomes in RA and, 1879
Stem cells
cyclophosphamide and autologous blood stem cell rescue in severe RA, 2286
transplantation in refractory RA, 2281
transplantation in SSc, 807
Steroids. *See also* Corticosteroids
fat conversion of marrow and treatment with, 1405
intravenous, in prevention of leg length discrepancy in pauciarticular JRA, 2330
joint lavage and steroid injection in knee arthritis, 475
Stiff-man syndrome, 1312
Stillman, James Sydney, obituary, 1087
Still's disease, cerebral vasculitis associated with *Mycobacterium tuberculosis* in, 383
Streptococci, in psoriatic arthritis peripheral blood and synovial fluid, 2055
Stromelysin I, collagen damage initiation and, 2074
Sugar printing, IgG oligosaccharides in rheumatic disease, 1682
Sulfapyridine, chemotaxis inhibition in endothelial cells in RA and, 1927
Sulfasalazine
chemotaxis inhibition by, in endothelial cells in RA, 1927
in peripheral arthritis in seronegative spondylarthropathies, 2325
Synovial cells, tumor necrosis factor α and Fas-mediated apoptosis in, 519
Synovial fibroblasts
collagenase 3 in RA, 1517
gene transfer of cytokine inhibitors into, 490
p53 gene in RA, 1594
Synovial fluid
aggrecan turnover in, 534
bacterial components in *Salmonella*-triggered reactive arthritis, 84
CCR5 chemokine receptor in effusions of, 981
CD146 in RA, 622
detection of bacterial DNA in septic arthritis, 2198
metalloproteinase inhibitors and cartilage breakdown in OA, 129
Streptococci as molecular markers, in psoriatic arthritis, 2055
transforming growth factor β and dendritic cells, 507
Whipple's disease diagnosis by molecular analysis of, 1777
Synovial tissue
adhesion molecules in, 1067
annexin I inhibition in rat adjuvant arthritis, 1538
antibiotic resistance to *Borrelia burgdorferi* in arthritis in Lyme disease, 2705
cathepsin K mRNA in giant cells in OA, 1588
CD97 and CD55 expression in rheumatoid, 650
Chlamydia pneumoniae in arthritis, 1889
chondroprogenitor cells of, 2631
collagenase 3 in RA, 1517
fluoxetine and amitriptyline inhibitory effects in, 2561
human DnaJ homologs in RA, 210
IL-17 in RA, 963
nurse-like cells in RA, 221
Synoviocytes
CD97 and CD55 expression in RA, 650
IL-7 and IL-15 production by RA fibroblast-like, 1508
taurine chloramine inhibitory function in RA, 2552
tumor necrosis factor α and Fas/Fas ligand–mediated apoptosis in, 519
Synovitis
bone changes in early untreated RA and, 1706
HLA alleles associated with early, 1696
HLA-DR1 in polymyalgia rheumatica and, 1561
telomerase activity in pigmented villonodular, 669

Synovitis *(cont'd)*
vascular patterns of early, 1481
Synovium, *Chlamydia trachomatis* nucleic acids in asymptomatic subjects, 1281
Systemic Lupus Activity Measure, 1354
Systemic lupus erythematosus (SLE)
after hepatitis B vaccination, 1307
anti-β_2 glycoproteins and HLA class II alleles, 268
anticardiolipin antibodies and cognitive function in, 728, 735
anti-C1q autoantibodies and nephritis in, 187
anti–endothelial cell antibodies in, 631
anti–lamin B1 and lupus anticoagulant in, 1347
antiphospholipid antibody production and environmental factors in, 1062
apoptotic defects with CD95 mutations in, 1833
–associated catastrophic antiphospholipid syndrome and typhoid fever, 1056
β_2-glycoprotein I polymorphisms in, 1189
carotid plaque in, 51
CD40 in, 871
chromosome 1q41 linkage with, 1902
complement deficiency and infection risk in, 2023
"cure" and, 1552
EBV as risk factor for in children and adolescents, 1782
estrogen enhancement of antibodies in, 328
ethnicity and, 1560
fat conversion in marrow in treatment with steroids in, 1405
Fcγ receptor type IIa polymorphisms in, 1823, 1828
fractures in, 882
hospital experience and mortality in, 891
human retrovirus 5 in, 448, 2492
IL-10 and, 2017
IL-10 in multicase families with, 1649
incidence and mortality trends of, 46, 2021
long-term remission with allogenic bone marrow transplantation and, 1777
mannose-binding lectin polymorphisms and infections in, 2145
morbidity in, 338
neuropsychiatric, ACR nomenclature for, 599
neuropsychiatric, IL-6 in, 2730
neuropsychiatric, neuroimaging in, 2026
neuropsychiatric and regional cerebral blood flow, 61
nucleosomes in, 833, 2733, 2734
ovarian failure and flares of, 1274
poly(ADP-ribose) polymerase alleles and susceptibility to antiphospholipid syndrome or, 2194
polymorphisms in, 1298
prevalence in US, 396
procainamide-induced, 1300
referral and management guidelines for, 1785
regional cerebral blood flow and brain glucose metabolism in, 61
RP105-negative B cells in, 2593
SLE disease activity patterns, 2682
sleep disturbances in, 2189
spinal epidural hematoma complicating active, 577
Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in, 1354
T cell protein kinase A-I in, 1458
T cell receptor ζ chain in, 1908, 2601
thrombotic thrombocytopenic purpura in childhood, 2346
thromboxane biosynthesis in, 2689
Th1/Th2 balance of peripheral T cells in, 1644
vasculitis in Palmerston North mouse model, 561
Systemic Lupus Erythematosus Disease Activity Index, 1354
Systemic sclerosis (SSc)
anti-RNA polymerase antibodies and, 275
Systemic sclerosis (SSc) *(cont'd)*
–associated pulmonary hypertension and epoprostenol, 2638
cytomegalovirus antibodies in, 389
differential expression of mRNA in, 1451
endothelial apoptosis in, 2491
ethnic differences in, 465
fertility and pregnancy outcome in, 763
fibrillin 1 autoantibodies in localized, 2656
five-year survival model for, 2660
HAQ in, 2372
high-dose vs. low-dose D-penicillamine in early diffuse, 1194
IFNα therapy in, 299
iloprost treatment in, 196
lack of endothelial cell apoptosis in mouse, 581
losartan for, 2646
pericyte activation in Raynaud's phenomenon and, 930
stem cell transplantation in, 807
topoisomerase I epitope and, 1179
type 2 cytokines in lung disease in, 1168
watermelon stomach in, 573

T

Takayasu arteritis
anti–endothelial cell antibodies in, 1421
gadolinium-enhanced MRI in, 1549
Taurine chloramine, inhibitory function in synoviocytes in RA, 2552
T cell receptor ζ, chain, in SLE, 1908, 2601
T cell receptors
in spontaneous murine arthritis, 2517
usage among Sm-B–specific T cell clones, 703
T cells. *See also* Cytokines
CD4+ apoptosis and disease activity in SS, 1673
differential function of HLA-DRB4*0401 and HLA-DRB4*0402 in RA, 1497
Fas/Fas ligand and apoptosis in inflammatory myopathies, 291
monoclonal anti–tumor necrosis factor α and Th1 CD4+ in RA, 2166
proliferation in RA and p205, 971
protein kinase A-I in SLE, 1458
reactivity to outer surface protein A in Lyme arthritis, 1813
receptor ζ chains in SLE, 1908, 2601
response to collagen II in RA, 2085
termination of histone-specific anergy of, 2449
Th1/Th2 balance of peripheral, in SLE, 1644
transforming growth factor β and dendritic cells in RA and, 507
vasculitis in Palmerston North mouse model and, 561
Telomerase, activity in RA and pigmented villonodular synovitis, 669
Temporal artery biopsy
in diagnosis of systemic necrotizing vasculitis, 2674
parvovirus B19 in pathogenesis of giant cell (temporal) arteritis, 1255
Tender points, in fibromyalgia, 1397
Thalidomide
ovarian failure and, 2259
in treatment of refractory ankylosing spondylitis, 580
Th1 cytokines
disease chronicity and reactive arthritis, 2039
drug resistance in RA and, 2014
IL-17 in RA synovial tissue and, 963
immune response in Behçet's disease and, 1967
monoclonal anti–tumor necrosis factor α and CD4+ T cells in RA, 2166
/Th2 balance of peripheral, in SLE, 1644
in Wegener's granulomatosis, 742
Th2 cytokines
disease chronicity and reactive arthritis, 2039
/Th1 balance of peripheral, in SLE, 1644

Thioredoxin, expression in RA, 2430
Thrombotic thrombocytopenic purpura, SLE and, 2346
Thromboxane, biosynthesis in SLE, 2689
Tissue inhibitor of metalloproteinases
  matrix metalloproteinase inhibitors and cartilage breakdown in OA, 129
  metalloproteinase inhibitors and cartilage breakdown in OA, 129
  serum levels in RA, 1861
Tongue, geographic, 1061
Topoisomerase I epitope and SSc, 1179
Tramadol, OA pain and naproxen and, 1370
Transcription factors, signal transduction and, 609
Transforming growth factor β
  apoptosis induction by proteasome inhibitor and, 2440
  avocado/soybean unsaponifiables and articular chondrocyte expression of, 148
  chondrocytes in OA and, 1147
  chondroprogenitor cells of synovial tissue and, 2631
  collagenase regulation in OA by, 719
  effects on dendritic cells, 507
  modulation of oral tolerance to type II collagen by, 110
  nitric oxide inhibition of production by chondrocytes, 248
Transplantation, stem cell, 807, 2281
Tropheryma whippelii, polymerase chain reaction detection of, 812
Tuberculosis, of wrist, 2724
Tumor necrosis factor α
  apoptosis induction by proteasome inhibitor, 2440
  Fas-mediated apoptosis in synoviocytes and, 519
  gene polymorphisms and HLA genes in JRA, 2577
  IFNβ gene therapy in murine collagen-induced arthritis and, 90
  IL-12 regulation of murine collagen-induced arthritis and, 100
  –induced prostaglandin E_2, cytokine inhibition of, 710
  macrophage migration inhibitory factor in RA and, 1601
  microsatellite polymorphism and RA severity, 438
  microsatellite polymorphisms and RA outcome, 2698
  monoclonal anti–, and Th1 CD4+ T cells in RA, 2166
  opsonized dendritic cells and, 1412
  RA synovial cell production of IL-12 and, 1917
  synovial nurse-like cells in RA, 221
  thioredoxin expression in RA and, 2430
Tumor necrosis factor receptor p55, *Yersinia enterocolitica*–associated arthritis in mice, 1662
Twins
  MRI study of disk degeneration in, 366
  sacroiliitis, hyperostosis sternoclavicularis, and psoriasis palmoplantaris in, 574
Typhoid fever, SLE-associated catastrophic antiphospholipid syndrome and, 1056

U

Ultrasound
  in assessment of arthritis in finger joints, 1232
Ultrasound *(cont'd)*
  high-resolution, of metacarpophalangeal and proximal interphalangeal joints in RA, 2303
Urokinase plasminogen activity, regulation by insulin-like growth factor I in human osteoblasts, 2112
Uveitis, ciprofloxacin in reactive arthritis and anterior, 1894

V

Vasculitis. *See also* Necrotizing vasculitis
  anti–endothelial cell antibodies in systemic, 631
  cerebral, associated with *Mycobacterium tuberculosis*, 383
  cryoglobulinemic, 2507
  giant cell (temporal) arteritis and temporal artery biopsy in diagnosis of systemic necrotizing, 2674
  localized bowel, 182
  microscopic polyangiitis, 421
  in Palmerston North mouse lupus model, 561
  rarity in Africa, 2497
Vasculitis Activity Index validation, for necrotizing vasculitis, 2365
Vasculopathy, in Takayasu arteritis, 1421
Vasoactive intestinal peptide, in modulation of RA synovial cell function, 2418
Vitamin D
  corticosteroid-induced osteoporosis and, 1740
  in OA, 854

W

Watermelon stomach, in SSc, 573
Wegener's granulomatosis
  antineutrophil cytoplasmic antibodies associated with, 384, 2494
  FcγR polymorphisms in, 1823
  patients' perception of, 2495
  recombinant human granulocyte colony-stimulating factor in, 1752
  with renal cell carcinoma, 751
  staged approach in treatment of, 2666
  Th1 subset in, 742
Whipple's disease
  diagnosis by molecular analysis of synovial fluid, 1777
  hypertrophic osteoarthropathy in, 2002
  polymerase chain reaction detection of, 812
Wrist, tuberculosis of, 2724

Y

Yersinia enterocolitica–associated arthritis in tumor necrosis factor receptor p55 mice, 1662
Yersinia pseudotuberculosis, in reactive arthritis, 2239
Y2K, strategic alliances, and you, 406
YKL-40, giant cell arteritis and, 2624